 
               NCT 02250651  
 
Study ID: 192024 -092 
 
 
Title: The Efficacy and Safety of Bimatoprost SR in Patients With Open- angle 
Glaucoma or Ocular Hypertension  
 
                                Protocol Date: June 5, 2018  
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 1 GDD-TA-T-004 v2013.9 
 Title Page 
ALLERGAN – CONFIDENTIAL 
The following contains confidential, proprietary information  
which is the property of Allergan 
 
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or 
Ocular Hypertension 
 
Protocol Number:   192024-[ADDRESS_696366] Number: 2014-003186-24  
Phase: [ADDRESS_696367]: Bimatoprost SR 
Sponsor: Allergan (North America) 
[ADDRESS_696368] 
Irvine, [LOCATION_004] [LOCATION_003] [ZIP_CODE] +[PHONE_10421] +[PHONE_10422] 
 Allergan Ltd. 
1st Floor, Marlow 
International, The Parkway, Marlow Buckinghamshire SL7 1YL [LOCATION_008] Tel: +44 (0) 1628 494444 
Fax: +44 (0) 1628 494449  
Emergency Telephone Numbers: Refe r to the Study Contacts Page. 
Serious Adverse Event Reporting 
Fax Numbers:  
(Backup Fax No.: )   
 
Allergan Medical Safety Physician Contact [CONTACT_7171]:  
Tel (office):   
Tel (mobile):   
Fax:   
Email:  

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 2 GDD-TA-T-004 v2013.9 
 Allergan Signatory:  
Vice President and  
Therapeutic Area Head 
Anterior Segment and Consumer Eye Care 
Allergan – Global Drug Development 
Refer to the final page of this protocol for electronic signature 
[CONTACT_51472]. 
 
The following information can be found on FDA Fo rm 1572 and/or study contacts page:  name [CONTACT_13255] [CONTACT_535369]; name, address, 
and statement of qualifications of each investigat or; name [CONTACT_535414]; name [CONTACT_535415]; name [CONTACT_535416] (IRB); US 21 CFR 312.23 section 6(iii)b. 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 3 GDD-TA-T-004 v2013.9 
 INVESTIGATOR SIGNATURE [CONTACT_249625]:  
  
 
I agree to: 
• Implement and conduct this study diligently a nd in strict compliance with the protocol, 
good clinical practices and all ap plicable laws and regulations 
• Maintain all information supplied by [CONTACT_535370], and when this information 
is submitted to an institutional review boa rd (IRB), independent ethics committee (IEC) 
or another group, it will be submitted with a de signation that the material is confidential 
• Ensure that all persons assisti ng with the trial are adequately informed about the protocol, 
the investigational product(s), and their trial- related duties and functions. 
I have read this protocol in its en tirety and I agree to all aspects. 
     
Investigator Printed Name  [CONTACT_535417] :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696369] (LUMIGAN®) ................................................................................... [ADDRESS_696370] SR  .......................................................... 28 
1.4 Study Rationale  ...................................................................................................... 28 
2. Study Objectives and Clinical Hypotheses  ...................................................................... 29 
2.1 Study Objectives  .................................................................................................... 29 
2.2 Clinical Hypotheses  ............................................................................................... 29  
3. Study Design  .................................................................................................................... 29 
4. Study Population and Entry Criteria  ................................................................................ 31 
4.1 Number of Patients  ................................................................................................. 31 
4.2 Study Population Characteristics  ........................................................................... 31 
4.2.1 Patients With Sickle Cell Trait or Disease  ................................................. 31 
4.3 Inclusion Criteria  .................................................................................................... 31 
4.4 Exclusion Criteria ................................................................................................... 33  
4.5 Permissible and Prohibited Medications/Treatments  ............................................. 37 
4.5.1 Permissible Medications/Treatments  ......................................................... 37 
4.5.2 Prohibited Medications/Treatments  ........................................................... 38 
4.5.3 Definition of Females of (Non-)Childbearing Potential and/or Acceptable 
Contraceptive Methods  .............................................................................. 40 
5. Study Treatments  ............................................................................................................. 41 
5.1 Study Treatments and Formulations  ...................................................................... 41 
5.2 Control Treatments  ................................................................................................. 41 
5.3 Methods for Masking  ............................................................................................. 41 
5.4 Treatment Allocation Ratio and Stratification  ....................................................... 43 
 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 5
5
5
5
5
5
6. R
6
6
6
6
6
6
7. S
7
7
7gan Confidenti a
5.5 Metho
5.6 Treat m
5.6.1 
5.7 Stora g
5.8 Prepa r
5.9 Treat m
5.9.1 
5.9.2 
5.9.3 
5.9.4 
5.10 Retre a
Response M
6.1 Effica c
6.1.1 
6.2 Safety 
6.3 Other M
6.4 Exami
6.4.1 
6.4.2 
6.4.3 
6.5 Other S
6.6 Summ
Statistical P r
7.1 Analy s
7.2 Collec7.2.1
 
7.2.2 
7.3 Hypot h
7.3.1 al 
d for Assig n
ment Regim e
Treatment R
e of Study M
ration of Stu d
ment Admini
Patient Pre p
Study Trea
Administr a
Immediate 
atment  .........
easures and 
cy Measure s
Primary E f
Measures  ..
Measures ( O
nation Proc e
Medical H i
 M [IP_ADDRESS]
 P [IP_ADDRESS]
 V [IP_ADDRESS]
Pregnancy Laborator
y
 H [IP_ADDRESS]
 S [IP_ADDRESS]
 U [IP_ADDRESS]
Study Supp l
mary of Meth o
rocedures  ....
sis Populati o
tion and De r
Primary E f
Secondary 
hesis and M
Primary E fnment to Tre
en and Dosi n
Regimen/D o
Medications /
dy Medicati o
stration  .......
paration  ......
tment Loca t
ation Techni q
Posttreatm e
................... .
Summary o f
s .................. .
fficacy Mea s
................... .
Optional)  ......
edures, Test s
istory, Phys i
Medical His t
Physical Ex a
Vital Signs  ...
Testing  .......
y Procedures
Hematology  .
Serum Che m
Urinalysis  ....
lies ............. .
ods of Data 
................... .
ons .............. .
rivation of P
fficacy Vari a
Efficacy Va r
ethods of A n
fficacy Anal y
5 atment Gro u
ng ................ .
osage Adjus t
/Treatments  .
ons/Treatm e
................... .
................... .
tion ............. .
que ............. .
ent Observat
................... .
f Data Coll e
................... .
sure ............. .
................... .
................... .
s, Equipme n
ical Examin a
tory ............ .
amination .....
................... .
................... .
.................. .
................... .
mistry .......... .
................... .
................... .
Collection  ..
................... .
................... .
Primary and 
able ............. .
riable  ......... .
nalysis  ........ .
yses ............ .Pr
ups/Rando m
................... .
tments  ........ .
................... .
ents ............. .
................... .
................... .
................... .
................... .
tion ............. .
................... .
ection Meth o
................... .
................... .
................... .
................... .
nt, and Tech n
ation, and V i
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
Secondary E
................... .
................... .
................... .
................... .rotocol 192024
GDD-T Amization  ....... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
ods .............. .
................... .
................... .
................... .
................... .
niques  ......... .
ital Signs .....
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
Efficacy Ass
................... .
................... .
................... .
................... .4-092 Amend m
A-T-004 v2013................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
essments  .....
................... .
................... .
................... .
................... .ment 3 
.9 .... 43 
.... 44 
.... 44 
.... 45 
.... 46 
.... 46 
.... 46 
.... 46 
.... 47 
.... 47 
.... 48 
.... 48 
.... 48 
.... 48 
.... 49 
.... 52 
.... 52 
.... 52 
.... 52 
.... 53 
.... 53 
.... 53 
.... 53 
.... 54 
.... 54 
.... 54 
.... 54 
.... 55 
.... 55 
.... 56 
.... 56 
.... 57 
.... 57 
.... 57 
.... 57 
 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 [ADDRESS_696371] e
Study Visit S
8.1 Patien t
8.1.1 
8.1.2 
8.2 Wash o
8.3 Proce d
8.4 Visits a
8.4.1 
8.4.2 
8.4.3 al 
Secondary 
Other Effi c
Safety An a
oup Analyse
m Analyses ..
ses for US F
e Size Calc u
Schedule an d
t Entry Proc
Overview o
Informed C
out Intervals  
dures for Fi n
and Associa t
Screening V
Baseline Vi
Treatment P
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS] 1
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C 8.4.3.19Efficacy A n
cacy Analys e
alyses  .......... .
s ................. .
................... .
DA ............ .
ulation  ........ .
d Procedure s
edures  ........ .
of Entry Pro
Consent and 
................... .
nal Study En t
ted Procedu r
Visit ........... .
Visit ............. .
Period ........ .
Cycle 1:  Da y
Cycle 1:  Da y
Cycle 1:  Da y
Cycle 1:  W e
Cycle 1:  W e
Cycle 1:  W e
Cycle 1:  W e
Cycle 2:  W e
Cycle 2:  Da y
Cycle 2:  Da y
Cycle 2:  W e
Cycle 2:  W e
Cycle 2:  W e
Cycle 2:  W e
Cycle 3:  W e
Cycle 3:  Da y
Cycle 3:  Da y
Cycle 3:  W e
Cycle 3:  W e
6 nalyses  ........ .
es ................ .
................... .
................... .
................... .
................... .
................... .
s ................. .
................... .
cedures  .......
Patient Priv
................... .
try .............. .
res .............. .
................... .
................... .
................... .
y 1 Admini s
y 2 ............. .
y 4 and Da y
eek 2 ........... .
eek 6 ........... .
eek 12 ......... .
eek 15 ......... .
eek 16 Admi n
y 2 ............. .
y 4 and Da y
eek 18 ......... .
eek 22 ......... .
eek 28 ......... .
eek 31 ......... .
eek 32 Admi n
y 2 ............. .
y 4 and Da y
eek 34 ......... .
eek 38 ......... .Pr
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
vacy ............. .
................... .
................... .
................... .
................... .
................... .
................... .
stration Day  .
................... .
y 8 (Phone C
................... .
................... .
................... .
................... .
nistration D
................... .
y 8 (Phone C
................... .
................... .
................... .
................... .
nistration D
................... .
y 8 (Phone C
................... .
................... .rotocol 192024
GDD-T A................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
Calls) ........... .
................... .
................... .
................... .
................... .
ay .............. .
................... .
Calls) ........... .
................... .
................... .
................... .
................... .
ay .............. .
................... .
Calls) ........... .
................... .
................... .4-092 Amend m
A-T-004 v2013................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 3 
.9 .... 58 
.... 59 
.... 59 
.... 59 
.... 59 
.... 60 
.... 61 
.... 62 
.... 62 
.... 62 
.... 62 
.... 63 
.... 64 
.... 64 
.... 65 
.... 66 
.... 67 
.... 67 
.... 68 
.... 68 
.... 68 
.... 69 
.... 70 
.... 70 
.... 71 
.... 72 
.... 72 
.... 72 
.... 73 
.... 73 
.... 74 
.... 75 
.... 76 
.... 76 
.... 76 
.... 77 
 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8
8
8
8
8
8
9. A
9
9
9
9
10. A
1
1
1
1gan Confidenti a
8.4.4 
8.5 Instru c
8.6 Unsch e
8.7 Comp l
8.8 Early D
8.9 Withd r
8.10 Study 
Adverse Ev e
9.1 Defini t
9.1.1 
9.1.2 
9.1.3 
9.1.4 
9.2 Proce d
9.3 Proce d
9.4 Proce d
Administrat i
10.1 Protec t
10.1.1 
10.1.2 
10.1.3 
10.1.4 
10.2 Chang
10.3 Patien t
10.3.1 
10.4 Docu mal 
 C [IP_ADDRESS]
 C [IP_ADDRESS]
 C [IP_ADDRESS]
Extended F
 M [IP_ADDRESS]
 M [IP_ADDRESS]
 M [IP_ADDRESS]
 M [IP_ADDRESS]
ctions for th e
eduled Visit
liance with P
Discontinua t
rawal Criter i
Terminatio n
ents .............
tions ...........
Adverse E v
Serious A d
Severity  ...
Relationsh i
dures for Re p
dures for Re p
dures for Un m
ive Items  ....
tion of Hu m
Complianc
Relevant C
Complianc
CompliancComplianc
(US 21 CF
R
es to the Pr o
t Confidenti a
Patient Pri v
mentation  ....Cycle 3:  W e
Cycle 3:  W e
Cycle 3:  W e
Follow Up  ...
Month 14  .....
Month 16  .....
Month 18  .....
Month 20/E x
e Patients  .....
s ................. .
Protocol ...... .
tion of Patie
ia ................ .
n .................. .
................... .
................... .
vent ............ .
dverse Event
................... .
ip to Study D
porting Adv e
porting a Se r
masking of S
................... .
man Subjects  .
e with Infor m
Country Reg u
e With IRB 
e With Goo d
e With Elec t
R Part 11)  ...
otocol  ......... .
ality ........... .
vacy ........... .
................... .
7 eek 44 ......... .
eek 48 ......... .
eek 52 ......... .
................... .
................... .
................... .
................... .
xit ............... .
................... .
................... .
................... .
nts ............. .
................... .
................... .
................... .
................... .
................... .
.................. .
................... .
Drug or Stu d
erse Events  .
rious Adver s
Study Medi c
................... .
................... .
med Conse n
ulations  .......
or IEC Reg u
d Clinical P r
tronic Reco r
................... .
................... .
................... .
................... .
................... .Pr
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
dy Procedur e
................... .
se Event ..... .
cation  ......... .
................... .
................... .
nt Regulatio n
................... .
ulations  .......
ractice  ........ .
rds; Electro n
................... .
................... .
................... .
................... .
................... .rotocol 192024
GDD-T A................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
e ................. .
................... .
................... .
................... .
................... .
................... .
ns (US 21 C
................... .
................... .
................... .
nic Signatur e
................... .
................... .
................... .
................... .
................... .4-092 Amend m
A-T-004 v2013................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
FR Part 50) 
................... .
................... .
................... .
es Regulatio
................... .
................... .
................... .
................... .
................... .ment 3 
.9 .... 77 
.... 78 
.... 79 
.... 80 
.... 80 
.... 80 
.... 81 
.... 81 
.... 82 
.... 83 
.... 83 
.... 84 
.... 84 
.... 85 
.... 85 
.... 85 
.... 85 
.... 86 
.... 87 
.... 87 
.... 87 
.... 88 
.... 88 
.... 89 
.... 89 
and 
.... 89 
.... 89 
.... 89 
ns 
.... 90 
.... 90 
.... 90 
.... 90 
.... 91 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 8 GDD-TA-T-004 v2013.9 
 10.4.1 Source Documents  ..................................................................................... 91  
10.4.2 Case Report Form Completion ................................................................... 92 
10.4.3 Study Summary  .......................................................................................... 92 
10.4.4 Retention of Documentation  ...................................................................... 92 
10.5 Labeling, Packaging, and Return or Di sposal of Study Medications/Treatments  . 93 
10.5.1 Labeling/Packaging  .................................................................................... 93 
10.5.2 Clinical Supply Inventory  .......................................................................... 93 
10.5.3 Return or Disposal of Study Medi cations/Treatments and/or Supplies  ..... [ADDRESS_696372] of Tables 
Table 1  Treatment Groups  ........................................................................................... 10 
Table 2  Screening through Treatment Day 1  ............................................................... 15 
Table 3  Administration Cycle 1 Schedule of Vis its and Procedures: Treatment Period 
Day 2 through Week 12  .................................................................................. 17 
Table 4  Administration Cycle 2 Schedule of Vis its and Procedures:  Treatment Period 
Week 15 Through Week 28  ............................................................................. 18 
Table 5  Administration Cycle 3 Schedule of Vis its and Procedures:  Treatment Period 
Week 31 Through Week 52  ............................................................................. 20 
Table 6  Schedule of Visits and Procedures:  Extended Follow Up Months 14, 16, 18, 
and 20  .............................................................................................................. 22 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696373] of Figures 
Figure 1  Flowchart of Patient Participation  .................................................................. 14 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 10 GDD-TA-T-004 v2013.9 
 Protocol Summary 
 
Study Compound:  Bimatoprost sustained-release (SR) biodegradable implants containing preservative-free 
AGN-192024 (bimatoprost)  
Phase: 3 
Study Objectives:   
To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of [ADDRESS_696374] SR 
in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) after initial and repeated 
administrations  
Clinical Hypotheses:   
At least 1 dose strength (10 µg or 15 µg) of Bimatoprost SR will have an IOP-lowering effect that is noninferior 
to that of topi[INVESTIGATOR_535322] 0.5% (hereafter referred to as timolol) eye drops in patients 
with OAG or OHT following single and repeat administration. 
Bimatoprost SR administered intracamerally in dose streng ths of [ADDRESS_696375] an acceptable safety 
profile in patients with OAG or OHT following single and repeat administration. 
Study Design 
Structure : Phase 3, multicenter, randomized , masked, parallel-group comparison ([ADDRESS_696376] SR versus active control), repeat administration 
Duration : Approximately 22 months, consisting of screening of up to 28 days before washout, washout period 
of up to 42 days before initial administration of study medication, 52-week treatment period, plus 8 months 
extended follow-up  
Study Treatment Groups : Bimatoprost SR dose groups:  10 µg and 15 µg 
Control : Timolol eye drops plus Sham needleless procedure (that involves touching the eye at the area of 
insertion with a needleless applicator). Dosage/Dose Regimen: Patients will receive [ADDRESS_696377] SR  or Control treatment in the 
study eye on Day 1 (with repeat administration of the sa me dose strength or Sham at Week 16 and Week 32). 
Bimatoprost SR-treated patients will receive intracameral administration of  Bimatoprost SR in the study eye 
using a prefilled applicator.  Timolol vehicle eye drops will be used twice daily (BID; in the morning and 
evening) to mask the treatment of patients receiving Bimatoprost SR in the study eye.  The fellow eye will receive a Sham needleless procedure (hereafter called Sham administration or Sham administration procedure) 
plus topi[INVESTIGATOR_535323] , BID.  Control group patients will receive  a Sham administrati on plus timolol in 
both eyes. 
All patients will be masked to their treatment group.  Treatment groups are shown in  Table [ADDRESS_696378] SR 10 µg  Dose strength:  10 µg 
Eye drops:  Vehicle BID Sham administration procedure Eye drops:  Timolol BID 
Bimatoprost SR 15 µg Dose strength:  15 µg 
Eye drops:  Vehicle BID Sham administration procedure Eye drops:  Timolol BID 
Control Sham administration procedure 
Eye drops:  Timolol BID Sham administration procedure Eye drops:  Timolol BID 
BID = twice daily 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 11 GDD-TA-T-004 v2013.9 
 The patients will begin self-administration of the study-provided eye drops (vehicle or timolol) in both eyes, 
starting with the evening dose on the first administration (Bimatoprost SR or Sham administration) day visit.  
Patients will continue self-administration of the study-p rovided eye drops in the morning (08:00 ± 1 hour) and 
in the evening (20:00  ± 1 hour) approximately 12 hours apart throughout the study, with the exception of the 
morning of a subsequent visit, on which the morning eye drop administration will be performed at the study site. 
Randomization/Stratification : Randomization to treatment groups will use a 1:1:1 ratio (Bimatoprost SR 
10 µg:Bimatoprost SR 15 µg:Control).  Randomization will be stratified by [CONTACT_535371] 0 IOP 
(≤ 25 mm Hg or > 25 mm Hg). 
Visit Schedule: Patients who complete the entire study without r eceiving nonstudy IOP-lo wering medication in 
both eyes will have a minimum of 25 visits and 6 phone calls.  The schedule includes:  
• Screening (up to 28 days); Washout period of up to 42 days for both eyes (which may begin once 
screening procedures have been completed); Baseline (up to 3 days)  
• Treatment period  
o Cycle 1:  Day 1 Administration Day; Day 2; phone call on Days 4 and 8; and visits at Weeks 2, 6, 12, and 15 
o Cycle 2:  Week 16 Administration Day; Cycle 2 Day 2; phone call on Cycle 2 Days 4 and 8; and visits at Weeks 18, 22, 28, and 31 
o Cycle 3:  Week 32 Administration Day; Cycle 3 Day 2; phone call on Cycle 3 Days 4 and 8; 
and visits at Weeks 34, 38, 44, 48, and 52 
• Extended Follow-up 
o Visits at Months 14, 16, 18, and 20/Exit 
Intraocular pressure evaluations will occur at 2 timepoints:  Hour 0 (08:00 ± 1 hour) and Hour 2 
(Hour 0 + 2 hours [± 30 minutes]). 
Patients who have not received nonstudy  IOP-lowering medication (prohibited prior to Week 52) in both eyes 
will receive a repeat administration of  Bimatoprost SR (or Sham administration in Control group study eyes and 
all fellow eyes) at the Week [ADDRESS_696379] SR or Sham, at which time they ma y exit early at the investigator’s discretion. 
Study Population Characteristics 
Number of Patients : Approximately 510 patients will be enrolled in the study. 
Condition/Disease : Patients with OAG (primary OAG, pseudoexfoliative glaucoma, or pi[INVESTIGATOR_11232]) 
or OHT who require IOP-lowering medications in both eyes.  The eye that meets the entry criteria will be 
selected as the study eye.  If both eyes meet the entry criteria, the eye with the higher IOP at baseline Hour [ADDRESS_696380] the same IOP at Hour 0, then the right eye will be 
designated as the study eye. 
Key Inclusion Criteria :  
• Written informed consent has been obtained 
• Diagnosis of either OAG (ie, pr imary, pseudoexfoliation, or pi[INVESTIGATOR_535324]) or OHT in each 
eye and both eyes require IOP-lowering treatment (Not e:  diagnosis does not have to be the same in 
both eyes) 
• In the investigator’s opi[INVESTIGATOR_1649], either eye can be treat ed adequately with topi[INVESTIGATOR_535325]-blocker 
(eg, timolol) eye drops as the sole therapy  
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 12 GDD-TA-T-004 v2013.9 
 • In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated adequately with topi[INVESTIGATOR_358141], 
prostaglandin, or prostaglandin analog (eg, LUMIGAN, Xalatan, Travatan) eye drops as the sole 
therapy 
• The iridocorneal angle in the study eye must be independently confirmed as being qualified by 
2 ophthalmologists using the following criteria:  
a. Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior angle 
b. Peripheral anterior chamber dept h by [CONTACT_358184] ≥  1/2 corneal thickness  
Note: The independent eligibility assessments must both agree that the Shaffer grade is ≥ 3 and the 
Van Herick grade is ≥ 1/2 corneal thickness.  
• At the Baseline visit: Hour 0 IOP in the study eye of ≥  22 mm Hg and ≤ 32 mm Hg, and in the fellow 
eye of ≤ 32 mm Hg 
• At the Baseline visit: Hour 2 IOP in the study eye of ≥  19 mm Hg and ≤ 32 mm Hg, and in the fellow 
eye of ≤ 32 mm Hg 
• By [CONTACT_535372], the final central endothelial cell density in both eyes must be confirmed as being qualified by [CONTACT_535373], with at l east one eye qualified for in clusion as the study eye 
Key Exclusion Criteria : 
• The following surg ical history: 
a. History or evidence of complicated cataract surgery in the study eye: eg, surgery resulting in 
complicated lens placement (such as anterior ch amber intraocular lens implant [IOL], sulcus 
IOL, aphakia, etc) or intraoperative complications  (such as a posterior capsular tear [with or 
without vitreous loss], substantial iris trauma, etc) 
Note: history of uncomplicated catar act surgery is not an exclusion. 
b. History of phakic IOL insertion for refr active error correction in the study eye 
• In the investigator’s opi[INVESTIGATOR_1649], patient is nonresponsive to topi[INVESTIGATOR_535325]-blockers and/or 
topi[INVESTIGATOR_535326], prostaglandins, or prostaglandin analogs (eg, LUMIGAN, Xalatan, Travatan) 
• Contraindications to beta-blocker therapy 
Response Measures 
Efficacy: Intraocular pressure measured by [CONTACT_535374] : Adverse events; ocular parameters as determined through assessment of visual acuity and visual field; 
evaluation of macroscopic bulbar conjunctival hyperemia and iris color; assessment of endothelial cell density 
and corneal thickness; IOP measurement, biomicroscopic and ophthalmoscopic examinations (including 
gonioscopy with Bimatoprost SR implant assessment, optic disc examination, and dilated fundus examination); 
and optical coherence tomogr aphy (OCT) of the macula 
General Statistical Methods and Types of Analyses:    
The intent-to-treat population (ITT) is defined as all randomized patients and will be used for demographic and 
efficacy analyses. The per protocol (PP) population will consist of the subset of the ITT population with no 
protocol deviat ions affecting the primary effi cacy analysis and will be used to confirm the primary efficacy 
analysis. A list of patients excluded from the PP population will be finalized prior to database lock. The safety population is defined as all patients who received study drug treatment and will be used for safety analyses. 
Analyses in the ITT population will be based on the treatment to which a patient was randomized, and analyses 
in both the PP and safety  populations will be ba sed on the actual treatment a patient received. 
Continuous variables will be summarized by [CONTACT_28272], mean, standard deviation, median, minimum, and maximum. Categori cal variables will be summarized by [CONTACT_7203]. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696381] SR  dose strength and timolo l for each hour (Hours 0 
and 2) using the ITT population. The comparisons at Week 12 will be considered the primary analysis. 
Intraocular pressure change from baseline will be analyzed using a mixed-effects model repeated measures 
(MMRM) approach.  The model will include IOP time-matc hed change from baseline as the response variable 
and treatment, timepoint (Hours 0 and 2 at each visit of Weeks 2, 6, and 12), treatment-by-timepoint interaction, and baseline IOP stratification as fixed effects. Unstructured covariance matrix will be used for repeated measures on the same patient; if the model with unstru ctured covariance matrix fails to converge, multiple 
imputation (MI) will be implemented before MMRM. 
Within the framework of this model, the mean differe nce between each Bimatopros t SR dose strength and 
timolol (Bimatoprost SR minus timolol) and the corresponding 2-sided 95% confidence interval will be 
provided for each hour (Hours 0 an d 2) at each visit. The formal noninf eriority test will be performed at 
Week [ADDRESS_696382] SR 15 µg (or 10 µg) will be declar ed noninferior to timolol if the upper limit of the 95% 
confidence interval is ≤ 1.5 mm Hg for both Hours 0 and 2 at Week 12.   
For the [LOCATION_002] Food and Drug Administration (US FDA), the primary efficacy variable will be the study 
eye IOP. The primary analysis will be based on Weeks 2,  6, and 12 using the ITT population. Specifically, the 
following analysis will be performed: IOP will be analyzed using an MMRM approach based on the same model as described for the primary efficacy analysis of time-matched IOP change from baseline. Within the 
framework of this model, the mean difference between each Bimatoprost SR dose strength and timolol group 
and the corresponding 95% co nfidence interval will be provided for each hour (Hou rs 0 and 2) and each visit 
(Weeks 2, 6, and 12). A gatekeepi[INVESTIGATOR_535327] I error rate at the 
0.[ADDRESS_696383] SR dose strength that shows noninferiority to timolol at all 6 timepoints with a 1.5 mm Hg margin (ie, the upper limit of the 95% confidence interval is ≤ 1.5 mm Hg) 
will be declared clinically noninferior to timolol if the upper limit of the 95% confidence interval is ≤ 1.0 mm Hg for 3 or more timepoints.   
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized for all events regardless of causality a nd for treatment-related adverse events. Ocular adverse 
events and safety variables will be tabulated by [CONTACT_535375], and nonocular safety variables will be summarized by [CONTACT_4676]. 
Sample Size Calculation: The sample size calculation is based on the primary efficacy  analysis of the IOP for 
US FDA review because the sample size based on the prim ary efficacy analysis for other regions is expected to 
be smaller. Based on simulations, a sample size of 486 patients (162 per group) will provide approximately 
95.1% and 83.5% power to show noninferiority (NI) of Bimatoprost SR [ADDRESS_696384] SR 10 µg, respectively, to timolol at all 6 scheduled timepoints based on an NI margin of 1.5 mm Hg and at 3 or more 
timepoints based on an NI margin of 1.0 mm Hg. Assuming a premature discontinuation rate of 5% within 
12 weeks (before the primary database lock), approximately 510 patients (170 per group) are to be enrolled into this study. 
 
 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 14 GDD-TA-T-004 v2013.9 
 Figure 1 Flowchart of Patient Participation 
 
 
  
 
 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 15 GDD-TA-T-004 v2013.9 
 Table 2 Screening through Treatment Day 1 

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 16 GDD-TA-T-004 v2013.9 
 

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 17 GDD-TA-T-004 v2013.9 
 Table 3 Administration Cycle 1 Schedule of Visits and Procedures: Trea tment Period Day 2 through Week 12 

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 18 GDD-TA-T-004 v2013.9 
 Table 4 Administration Cycle 2 Schedule of Visits and Procedures:  Treatment Period Week 15 Through Week 28 

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 19 GDD-TA-T-004 v2013.9 
  

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 20 GDD-TA-T-004 v2013.9 
 

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 21 GDD-TA-T-004 v2013.9 
  

 
 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 22 GDD-TA-T-004 v2013.9 
 Table 6 Schedule of Visits and Procedures:  Extended Follow Up Months 14, 16, 18, and 20 

 
 
 
Approval  Date:  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 23 GDD-TA-T-004 v2013.9 
  

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696385] types:  developmental, 
angle-closure, and open-angle glaucoma (OAG) ( Stamper et al, 2009).  Open-angle glaucom a 
is further categorized into primary OAG (POAG, sometimes also referred to as chronic 
OAG) and secondary OAG (which includes pi[INVESTIGATOR_535328]), 
the former being the predominant form of OAG.  Primary OAG is characterized as a multi-factorial optic neuropathy with a characteristic acquired atrophy of the optic nerve and loss of 
ganglion cells and their axons, developi[INVESTIGATOR_535329] e presence of open anterior chamber (AC) 
angles, and manifesting characteri stic visual field abnormalities ( American Academy 
of Ophthalmology, 2010a ).  It is estimated that 2.25 milli on people in the [LOCATION_002] (US) 
over the age of [ADDRESS_696386] POAG, half of whom are unaware of their disease despi[INVESTIGATOR_535330] ( Quigley, 1996).  Globally , over 60 million people are 
estimated to be affected by [CONTACT_78541] (the ma jority of whom have open angle glaucoma) and 
these numbers are expected to increase over time  (Quigley and Broman, 2006; 
Varma et al, 2011; Cook and Foster, 2012). 
Although many risk factors have been associated with OAG, elevated intraocular pressure 
(IOP) remains the most prominent factor a nd the only factor existing that ophthalmic 
intervention can reliably affect ( Stamper et al, 2009 ).  A number of controlled trials have 
demonstrated that lowering IOP will slow or delay the appearance or progression of 
glaucomatous damage.  Large, randomized clinic al trials such as the Ocular Hypertension 
Treatme nt Study (OHTS) ( Kass et al, 2002 ) and the Early Manifest Glauco ma Trial (EMGT) 
(Heijl et al, 2002 ) addressed the value of early detec tion and lowering of elevated IOP in 
ocular hypertension (OHT) or POAG.  The effect s and parameters of va rious interventions in 
eyes with established glaucomatous damage were addressed by [CONTACT_535376] (CIGTS) (Lichter et al, 2001 ) and the Advanced Glaucoma 
Intervention Study (AGIS) ( AGIS, 2000).  The currently availabl e approaches to lowering 
IOP include pharmacological therapy, laser trabeculoplasty, incisional surgery, and 
cyclodestructive procedures.  Each of these approaches has its own risk-benefit ratio.  
Because the risk-benefit ratio w ith drug therapy appears to be lower than that of surgical 
procedures, both historical and contemporary practice has been to attempt pharmacological 
treatment before resorting to other more invasive alternatives. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 25 GDD-TA-T-004 v2013.9 
 Patient nonadherence to topi[INVESTIGATOR_535331], as consistent IOP reducti on is associated with reduced risks of the 
development and progression of optic nerve dama ge (Friedman, 2009; Tsai, 2009 ).  In 
patients that are nonadherent to medical therapy, guidelines ar e provided to clinicians for 
assisting patients with being adherent (Budenz, 2009).  Nevertheless, frequently, patients 
with OAG or OHT not taking their medications w ill require incisional surgery to control the 
IOP.  Some of the disadvantages of performi ng incisional surgery include the significant 
sight-threatening complications that can occur wi th surgery, such as the globe perforation, 
suprachoroidal hemorrhage, hypotony maculopath y, corneal decompensation, and cataract 
formation or progression that may occur with filtering surg ery (Mosaed et al, 2009 ).  Given 
the risks associated with incisional surgery,  sustained-release formulations of ocular 
antihypertensive drugs are in deve lopment as an alternative to surgery for the management of 
elevated IOP ( Knight and Lawrence,  2014 ). 
1.[ADDRESS_696387] (LUMIGAN®) 
Bimatoprost is a member of a series of unique prostanoid compounds that are potent and 
efficacious ocular antihypertensi ve agents ( Woodward et al, 1994, 2001, and 2004 ).  
Bimatoprost appears to mimic the activ ity of biologically active prostamides 
(Study BIO-99-308; Matias et al, 200 4).  Chem ically, prostamides differ from prostaglandin 
analogs by [CONTACT_535377] ( Krauss and Woodward, 2004 ).  
Prostamides can be biosynthetically derived from anandamide, an endogenous membrane 
lipid (Kozak et al, 2002; Weber et al, 2004; W oodward et al, 2001; Yu et al, 1997).  The 
prostamide pathway leads to the biosynthesis of novel lipid amides that lower IOP. 
The IOP-lowering efficacy of LUMIGAN (bimat oprost ophthalmic solution) 0.03% is well 
established.  In phase 3 studies in patien ts with POAG or OHT, LUMIGAN administered 
once daily as monotherapy was superior to timolol at all tim epoints (Higginbotham  et al, 
2002).  This was further substantiated in the extension studies which followed patients in a 
masked manner for up to  4 years ( Cohen et al, 2004; Williams et al, 2008 ; 
Study 192024-014).  In clinical studies of patie nts with OAG or OHT with a mean baseline 
IOP of [ADDRESS_696388] of  LUMIGAN once daily in the evening was 7 to 
8 mm  Hg (Cohen et al, 2004; LUMIGAN® Package Insert, 2012; Williams et al, 2008 ). 
LUMIGAN was approved by [CONTACT_3133] (FDA) in 2001.  
Worldwide, LUMIGAN 0.03% is currently license d and marketed in more than 80 countries 
and LUMIGAN 0.01% is licensed and marketed in more than 40 countries.  Preservative-free 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696389] ophthalmic solution 0.03% has been approved since November [ADDRESS_696390] implant 
which is preloaded in an applicator for administration; together they comprise the Bimatoprost Sustained Release product (a nd will henceforth be referred to as 
Bimatoprost SR).  The Bimatoprost SR implant is injected into the AC via the corneal limbus using the prefilled applicator.  The biodegradable polymer matrix gradually degrades to 
carbon dioxide and water so that there is no need  to remove the Bimatoprost SR implant once 
the drug has been released.  The Bimatoprost SR implant used in this study contains total preservative-free bimatoprost loads of 10 µg or  15 µg, to provide average daily release (as 
determined by [CONTACT_254925]) of approximately [ADDRESS_696391], a typi[INVESTIGATOR_2855] 35 µL drop of LUMIGAN 
0.03% contains approximately [ADDRESS_696392] SR implant is exp ected to release drug over approximately 3 to 
4 months, and > 75% polymer matrix degrad ation is expected within approximately 
[ADDRESS_696393] SR implant exceeds the drug release duration, experien ce from preclinical studies, the phase 1/[ADDRESS_696394] SR 
Pharmacology, toxicology, and pharmacokinetic studies with multiple dose strengths, implant sizes and formulations (Generation 1 and Gene ration 2) of Bimatoprost SR were done in 
2 species (Beagle dog, Cynomolgus monkeys) with  a range of anterior chamber angle sizes 
in order to support the clinical  program.  These studies build  on the already considerable 
amount of nonclinical and clin ical information available for topi[INVESTIGATOR_358149] (see 
Investigator’s Brochure for additional details). 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 27 GDD-TA-T-004 v2013.9 
 Nonclinical studies with pharmacology e ndpoints (Reports BIO-09-803, BIO-11-920, 
PK09109-PK, BIO-09-785) showed dose-relate d reductions in IOP in normotensive 
Cynomolgus monkeys and Beagle dogs, as well as in laser-induced ocular hypertensive 
Cynomolgus monkeys following single doses.  Toxi cology studies, of at least [ADDRESS_696395] SR administration, were conducted in 
Cynomolgus monkeys and Beagle do gs (TX09051-TX, TX09066-TX, TX10016-TX, 
TX11076-TX, TX12012-TX, TX12018-TX, and TX12102-TX).  Monkeys, which have a characteristically small anterior chamber angl e compared to both dogs and humans, did not 
tolerate Bimatoprost SR dose strengths tested ( ≥ [ADDRESS_696396] SR) due to chronic 
contact [CONTACT_535378] .  Single and repeat oc ular toxicity studies 
with Generation [ADDRESS_696397] SR in dogs w ith varying AC angle sizes demonstrated 
acceptable safety and ocular tolerability with single doses ≤ 20 µg (TX11076-TX, 
TX12012-TX, TX12018-TX) and with repeat doses of ≤ 15 µg (TX12012-TX, 
TX12018-TX).  Furthermore, no adverse drug- or implant-related ocular findings have been 
seen following three intracameral injections of up to 20 µg (two 10 µg implants) Bimatoprost 
SR in the 18-month repeat dose Good Laboratory Practice (GLP) study in dogs (Report TX12102-TX). 
Pharmacokinetic studies (PK09109-PK, PK11086- PK) in Beagle dogs demonstrated that 
systemic exposure of bimatoprost and bimat oprost acid was below the limit of quantitation 
(BLQ) with doses ≤ 60 µg.  Aqueous humor concentrations generally peaked by 10 weeks 
postdose for doses ≤ 30 µg (Generation 1 and Generation 2), then declined to low levels 
suggestive of near-complete drug release from the device at 3 months for doses ≤ 20 µg.  By 
14 weeks following a 20 µg (Generation 2) dose, ocular tis sues samples were collected for 
analysis, which demonstrated that drug and me tabolite concentrations were BLQ in aqueous 
humor, vitreous humor, retina, and the remnant im plants, but detected in cornea, choroid, and 
iris-ciliary body.  A pharm acokinetic study (PK14025-PK) was conducted in Beagle dogs 
comparing the ocular distribution of topi[INVESTIGATOR_358149] 0.03% solution or a single 
Generation [ADDRESS_696398] SR implant (15 µg).  Following topi[INVESTIGATOR_78086], 
bimatoprost and bimatoprost acid distributed in to the iris-ciliary body as well as other (off 
target) tissues with concentrations in the bulbar conjunctiva, eyelid margin, and periorbital 
fat significantly higher than those observed in the iris-ciliary body. In contrast, following 
administration of a single Generation [ADDRESS_696399] acid concentrations were either below the limit of quantitation (BLQ) or near the 
detection limit in bulbar conjunctiva, eyelid ma rgin, and periorbital fat while the highest 
bimatoprost and bimatoprost acid concentrations were observed in the target tissue, the iris 
ciliary body. Retinal concentrations were BL Q following both topi[INVESTIGATOR_535332]. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 28 GDD-TA-T-004 v2013.9 
 1.3.2 Other Biodegradable Ocular Implants 
A number of sustained-release drug delivery implants using the Allergan biodegradable 
polylactic acid (PLA ) and/or polylactic- co-glycolic acid (PLGA) NOV ADUR® drug delivery 
system  preceded the development of the Bimatoprost SR implant.  The extensive clinical 
experience with previous intraocular implants de monstrates the safety and tolerability of an 
intraocular biodegradable implant administered into the eye via an applicator system.  For 
example, late phase clinical trials of sustaine d-release implants have been completed for the 
OZURDEX® dexamethasone intravitreal implant us ing the NOV ADUR drug delivery system 
for intraocular injections.  Because Bimatopros t SR is similar to OZURDEX in a number of 
aspects and uses the NOV ADUR drug delivery sy stem for intraocular injections, these data 
may be supportive of the safety and tole rability of Bimatoprost SR in humans. 
1.3.[ADDRESS_696400] SR 
Study 192024-041D was a Phase 1/2, paired-eye comparison evaluating the safety and 
efficacy of [ADDRESS_696401] SR (6 µg, 10 µg, 15 µg, or 20 µg [2 × 10 µg 
implants]), as single or repeat administration in one eye (study eye), versus the use of topi[INVESTIGATOR_535333]® 0.03% in the fellow eye (nonstudy eye).  The objective of this study was to 
evaluate the safety and IOP-lowering efficacy  of Bimatoprost SR in patients with OAG. 
A total of [ADDRESS_696402] SR administration, and were considered 
related to the study drug admini stration procedure.  There were no reports of serious study 
drug-related adverse events, and no new sa fety concerns were observed after the second 
treatment.  Please refer to the Investigator’s Brochure for details on reported safety findings. 
1.4 Study Rationale 
In the 192024-041D Phase 1/[ADDRESS_696403] SR provides 
IOP-lowering efficacy similar to topi[INVESTIGATOR_535334] :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696404] SR at dose 
strengths of 20 µg (2 × 10 µg) or less in the Phase 1/[ADDRESS_696405] SR will be compared versus a control group treated with 
the active comparator, topi[INVESTIGATOR_535335] 0.5%.  Timolol is a well-established 
treatment for IOP lowering in glaucoma and OH T, and has been used as a comparator in 
other IOP-lowering studies (Weinreb and Kaufma n, 2009). 
2. Study Objectives and Clinical Hypotheses  
2.1 Study Objectives 
• To evaluate the IOP-lowering efficacy and sa fety of [ADDRESS_696406] 
SR in patients with OAG or OHT after initial and repeated administrations 
2.2 Clinical Hypotheses 
• At least 1 dose strength (10 µg or 15 µg) of Bimatoprost SR will have an 
IOP-lowering effect that is  noninferior to that of topi[INVESTIGATOR_535336] 0.5% (hereafter referred to as tim olol) eye drops in patients with OAG or 
OHT following single and repeat administrations. 
• Bimatoprost SR administered intracamerally in dose strengths of [ADDRESS_696407] an acceptable safety profile in pa tients with OAG or OHT, following single and 
repeat administrations. 
3. Study Design 
This study is a multicenter, dose-ranging, randomized, parallel-group, patient and 
efficacy-evaluator masked 52-week evaluation (52-week treatment period with 8 months 
extended follow-up) of the safety and efficacy of Bimatoprost SR compared to timolol twice 
daily (BID) in patients with OAG or OHT.  Th e patients and the evaluators of the primary 
endpoint (IOP) will be masked to the treatment received.  The site coordinator and designated 
staff will not be masked to whether the patient received [ADDRESS_696408] SR or the Sham ad ministration, but will be masked to the specific dose strength 
that the patient receives.  Vehicle eye drops will be used BID to mask the treatment of 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696409] udy eye.  The fellow eye will receive a Sham 
administration plus topi[INVESTIGATOR_535337].  Control group patients will receive a 
Sham administration plus timolol in both eyes (see Table 7 ).  The study will be conducted at 
approximately [ADDRESS_696410] SR dose strengths (10 µg or 15 µg) will be tested in this study.  Patients 
will receive a scheduled second administration of  Bimatoprost SR at [ADDRESS_696411] scheduled ad ministration at 16 weeks following the second 
administration (ie, 32 weeks after the initial administration).  Control group patients will 
receive Sham administrations at all administration visits. 
Table [ADDRESS_696412] SR 10 µg Dose strength: 10 µg Sham administration procedure 
Eye drops:  Vehicle BID Eye drops:  Timolol BID 
Bimatoprost SR 15 µg Dose strength: 15 µg Sham administration procedure 
Eye drops:  Vehicle BID Eye drops:  Timolol BID 
Control Sham administration procedure Sham administration procedure 
Eyedrops:  Timolol BID Eyedrops:  Timolol  BID 
BID = twice daily 
 
Patients will begin self-administration of the study-provided eye drops in both eyes starting 
with the evening dose on the first administrati on (Day 1) visit (at which they will receive 
Bimatoprost SR administration or Sham ad ministration).  Patients will continue 
self-administration of study-provided eye drops in the morning (at 08:00 ± 1 hour) and in the 
evening (at 20:00 ± 1 hour), which is approximately 12 hours apart.  Patients will be 
instructed not to administer their drops on the morning of a study visit.  Drops will be 
administered immediately after the Hour 0 IOP measurement. 
The duration of the study for each patient is ap proximately 22 months (screening duration of 
up to [ADDRESS_696413] administration, 
plus the 52-week treatment period, plus 8 m onths extended follow-up).  Patients will be 
followed for at least [ADDRESS_696414] SR (or Sham) administration, and 
may exit early at or after the twelfth month fo llowing the last administration if there are no 
safety concerns in the op inion of the investigator. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 31 GDD-TA-T-004 v2013.9 
 4. Study Population and Entry Criteria 
4.1 Number of Patients  
Enrollment of approximately 510 patients in total at approximately 180 sites, with 
approximately 170 patients per group, is planne d to ensure 162 completed patients per group, 
assuming a premature discontinuation rate of 5%. 
4.2 Study Population Characteristics 
The study population consists of patients with OAG or OHT and an ope n iridocorneal angle 
inferiorly by [CONTACT_535379], and OAG or OHT in the fellow eye, where 
both eyes require IOP-lowering medication.  The eye that meets the entry criteria 
(Sections 4. 3 and 4.4) will b e selected as the study eye.  If both eyes meet the entry criteria, 
the eye with the higher IOP at Baseline Hour [ADDRESS_696415] the same IOP, then the right eye will be designated as the study eye. 
Angle qualification will be independen tly confirmed as being qualified by 
2 ophthalmologists, and endothelial cell dens ity qualification for study entry will be 
determined by [CONTACT_535380] (see Protocol 
Procedure Manual for details). 
4.2.1 Patients With Sickle Cell Trait or Disease 
Patients with sickle cell trait or disease (or other hemoglobinopathies) ma y be enrolled at the 
discretion of the investigator based on an individual risk-benefit assessment.  Because of a 
slightly higher risk of IOP elevation and intraocular complications in the setting of a 
microhyphema, patients with these disorders may undergo optional additional biomicroscopy 
and IOP measurements after injection/Sham in jection at the investigator’s discretion (see 
Section 8.4).  Additional information about the Bimat oprost SR experience in patients with 
sickle trait is provided in the Investigator’s Brochure. 
4.3 Inclusion Criteria 
The following are requirements for entry into the study: 
1. Male or female, ≥ 18 years of age 
2. Written informed consent has been obtained 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 32 GDD-TA-T-004 v2013.9 
 3. Written documentation has been obtained in acc ordance with the relevant country and 
local privacy requirements, where applicable (eg, Written Authorization for Use and 
Release of Health and Research Study Inform ation [US sites] and written Data Protection 
consent [EU sites]) 
4. Patient is willing to withhold his/her IOP- lowering treatments according to the study 
requirements, and in the opi[INVESTIGATOR_535338].  
5. Patient has the ability to understand and willingness to follo w study instructions and is 
likely to complete all required visits and procedures 
6. A negative pregnancy test result for females of childbearing potential at Baseline  
7. Diagnosis of either OAG (ie, primary, pseudoexfoliation, or pi[INVESTIGATOR_11232]) or OHT in each eye and both eyes require IOP-lowering treatment (Note:  diagnosis does 
not have to be the same in both eyes) 
8. In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated adequately with topi[INVESTIGATOR_535339]-blocker (eg, timolol) eye drops as the sole therapy   
9. In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated adequately with topi[INVESTIGATOR_358141], prostaglandin, or prostaglandi n analog (eg, LUMIGAN, Xalatan, Travatan) 
eye drops as the sole therapy   
10. The iridocorneal angle in the study eye mu st be independently confirmed as being 
qualified by 2 ophthalmologists using the following criteria: 
a. Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior angle 
b. Peripheral anterior chamber depth by [CONTACT_78546] ≥ 1/2 corneal 
thickness  
Note: The independent eligibility assessments must both agree that the Shaffer grade is 
≥ 3 and the Van Herick grade is ≥ 1/2 corneal thickness.  
11. At the Baseline visit, patient has been a ppropriately washed out of all IOP-lowering 
medications  

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 33 GDD-TA-T-004 v2013.9 
 12. At the Baseline visit:   
a. Hour 0 IOP in the study eye of ≥ 22 mm Hg and ≤  32 mm Hg, and in the fellow eye 
of ≤ 32 mm Hg 
b. Hour 2 IOP in the study eye of ≥ 19 mm Hg and ≤  32 mm Hg, and in the fellow eye 
of ≤ 32 mm Hg  
13. Central corneal endothelial cell density by [CONTACT_239796]: 
b. By [INVESTIGATOR_31975]:  final central endothelial cell density in both eyes must be confirmed 
as 
being qualified by [CONTACT_535381] t, with at least one eye qualified for 
inclusion as the study eye 
4.4 Exclusion Criteria 
The following are criteria for exclusi on from participating in the study: 
Non-ocular Criteria for Exclusion 
1. Uncontrolled systemic disease 
2. Female patients who are pregnant, nursing, or planning a pregnancy, or who are of 
childbearing potential and not using a reliab le means of contraception during the study 
(see Section 4.5.3) 
3. Known allergy or sensitivity to any study me dication or its components, any component 
of the delivery vehicle, procedure-related mate rials, or diagnostic agents used during the 
study (eg, topi[INVESTIGATOR_15413] , dilating drops, fluorescein) 
4. Contraindications to beta-blocker therapy

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 34 GDD-TA-T-004 v2013.9 
 5. Any condition which would preclude the pa tient’s ability 
to comply with study 
requirements, including completion of the study 
6. Patients who have a condition or are in a situ ation which, in the investigator’s opi[INVESTIGATOR_1649], 
may put the patient at significant risk, may confound the study results, or may interfere 
significantly with the patient’s participation in the study 
7. Anticipated use of oral, intramuscular, or in travenous corticosteroid s from [ADDRESS_696416] SR study 
Ocular Criteria for Exclusion 
11. In the investigator’s opi[INVESTIGATOR_1649], patient is nonresponsive to topi[INVESTIGATOR_535340]-blockers 
and/or topi[INVESTIGATOR_535326], prostaglandins, or prostagl andin analogs (eg, LUMIGAN, 
Xalatan, Travatan) 
12. History or evidence of clinical ly relevant, substantial ocular trauma (eg, a traumatic 
cataract, traumatic angle recession, etc) in the study eye  
13. The following surgical history: 
a. History or evidence of complicated cataract surgery in the study eye: eg, surgery 
resulting in complicated lens placement (suc h as anterior chamber intraocular lens 
implant [IOL], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear [with or without vitreous loss] , substantial iris trauma, 
etc). Note: history of uncomplicated cataract surgery is not an exclusion. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 35 GDD-TA-T-004 v2013.9 
 b. History of phakic IOL insertion for refr active error correction in the study eye 
14. Intraocular surgery (including cataract surgery) and/or any ocular lase r surgery within the 
6 months prior to treatment (Day 1) in the study eye 
16. Incisional refractive surgery (eg, radial kerato tomy), other than astigmatic keratotomy or 
limbal relaxing incisions in the study eye  

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696417] 
52 weeks of the study duration 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 37 GDD-TA-T-004 v2013.9 
 4.5 Permissible and Prohibited Medications/Treatments 
4.5.1 Permissible Medications/Treatments 
The fellow eyes of patients randomized to the Bimatoprost SR or Control groups will receive 
timolol BID for IOP lowering. 
Intermittent use of artificial tear products is allowed if they are not taken ≤ 15 minutes before 
any study procedure or ≤ 15 minutes before or after topi[INVESTIGATOR_535341].  Intermittent use of ocular decongestants or antihistamines is allowed if not taken 
within 2 days prior to a scheduled visit and/or ≤ [ADDRESS_696418] SR (or Sham) administration 
procedure. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 38 GDD-TA-T-004 v2013.9 
 Use of postoperative topi[INVESTIGATOR_535342], cortic osteroids, and non-steroidal 
anti-inflammatory drugs (NSAIDs) from the Administration Day (on Day 1, Week 16, and 
Week 32) to Day 7 following administration is allowed. 
Systemic beta-blocker containing medications  are permitted, provided that the dose/dosing 
regimen has remained stable for at least 2 months  prior to Screening, and is not anticipated to 
change during the duration of the study. 
Required surgical procedures may be performed in the fellow eye only after completion of 
Week 52. 
In addition, therapy considered necessary fo r the patient’s welfare may be given at the 
discretion of the investigator .  If concurrent medications may have an effect on study 
outcomes, these medications should be administered in dosages that remain constant 
throughout the entire duration of the study .  If the permissibility of a specific 
medication/treatment is in question, please contact [CONTACT_78562]. 
The use of systemic NSAIDs is also permitted. 
In the unlikely event that the Bimatoprost SR implant requires removal for significant safety 
reasons, this may be performed at the discre tion of the investigator following a discussion 
with the medical safety physician at Allergan (s ee Protocol Procedure Manual for details).   
Note that in the event that the investigator performs an unanticipated incisional surgical 
procedure on the study eye during which ocular fl uid is to be removed, ocular fluid/implant 
samples may be collected for analysis (see Prot ocol Procedure Manual fo r further details) at 
the investigator’s discretion.   
4.5.2 Prohibited Medications/Treatments 
The decision to administer a prohibited medicat ion and/or treatment is done with the safety 
of the study participant as the primary consideration.  When possible, Allergan should be 
notified before the prohibited medication/treatment is administered. During the study, patients should not participat e in other investiga tional drug or device 
studies. Nonstudy IOP-lowering Medications 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 39 GDD-TA-T-004 v2013.9 
 Use of any topi[INVESTIGATOR_535343], other than 
use of study medication (timolol) in  Control group or fellow eyes, is prohibited as concurrent 
therapy in either eye, unless necessary for the sa fety of the patient due to inadequate control 
of IOP as determined by [CONTACT_093].  Inadequate control of IOP should be confirmed at a 
subsequent visit (scheduled or unscheduled visit).  Prior to Week 52, the investigator will be 
expected to attest to the need for additional nonstudy IOP- lowering medication for safety 
reasons.  After the Week [ADDRESS_696419] udy topi[INVESTIGATOR_15434]-lowering medications will be 
permitted if in the investigator’s clinical judgment the IOP is not adequately controlled at two consecutive visits.  Initiation of medication in one eye should not automatically lead to 
initiation of medication in the other eye.  Each eye should be evaluated on  an individual basis 
when determining the need for additional nonstudy IOP-lowering medications.  If nonstudy 
IOP-lowering medication is initiated prior to Week 52, the investigator will be expected to attest to the need for additional nonstudy IO P-lowering medication for safety reasons for 
each eye individually.  
Contact [CONTACT_78563] [ADDRESS_696420] SR (or Sham) administration in either 
eye is prohibited.  
Contact [CONTACT_535382]-provided eye drops and 
patients should wait at least [ADDRESS_696421] lenses back in the eyes after 
instilling topi[INVESTIGATOR_15416]. 
Other Medications 
The following medications (or classes of medi cations) and treatment procedures are not 
permitted as concurrent therapy during th e study through [ADDRESS_696422] SR or Sham administration unless the patient has already been treated with 
nonstudy IOP-lowering medication in both eyes: 
• Subconjunctival, sub-Tenon’s, intravitreal, or other ophthalmic injections of any 
medications in either eye  
• Surgical procedures that are not related to Bimatoprost SR (or sham) administration 
procedures in the study eye (surgical procedures are allowed in the fellow eye after 
Week 52 as described in Section 4.5.1) 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 40 GDD-TA-T-004 v2013.9 
 • Use of any topi[INVESTIGATOR_20718]  (except as described above and in 
Section 4.5.1) in either eye. 
• Use of any ophthalmic (including topi[INVESTIGATOR_2855], in travitreal, sub-Tenon’s,  subconjunctival) 
corticosteroids in either eye from [ADDRESS_696423] administration, ex cept for use of postoperative topi[INVESTIGATOR_535344] 4.5.1. 
• Oral, intramuscular, or intravenous cort icosteroids from [ADDRESS_696424] injection. 
• Use of LATISSE® (bimatoprost for hypotrichosis) dur ing the study period in either 
eye  
• Systemic use of carbonic anhydrase inhibitors (eg, Diamox®)   
• Any initiation of or alterations in syst emic regimen of beta-blocker containing 
medications from 2 months prior to Screening through the final study visit 
4.5.3 Definition of Females of (Non -)Childbearing Potential and/or 
Acceptable Contraceptive Methods 
For purposes of this study, women will be considered of childbearing potential unless they 
are naturally postmenopausal or  permanently sterilized (ie,  hysterectomy).  Natural 
menopause is defined as the permanent ce ssation of menstrual periods, determined 
retrospectively after a woman has experienced 12 months of  amenorrhea without any other 
obvious pathological or physiological cause.  Fo r women of childbearing potential who may 
participate in the study, the following met hods of contraception, if properly used, are 
generally considered reliable:  hormonal contraceptives (ie, or al, patch, injection, implant), 
male condom with intravaginal spermicide, diaphragm or cervical cap with spermicide, 
vaginal contraceptive ring, intraute rine device, surgical sterili zation (bilateral tubal ligation, 
bilateral salpi[INVESTIGATOR_1656]), vasectomized partner, or true sexual abstinence (when this is in line with the preferred and usual lifestyle of the subject). 
The investigator and each patient  will determine the appropriate method of contraception for 
the patient during the participation in the study. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 41 GDD-TA-T-004 v2013.9 
 5. Study Treatments  
5.1 Study Treatments and Formulations 
5.2 Contr ol Tr eatments  
For Sham administration, a needleless applicator is provided. 
The following topi[INVESTIGATOR_535345]: 
• Timolol 0.5% ophthalmic solution  
 
 
 
• Timolol vehicle  is identical in  appearance to the 
timolol 0.5% ophthalmic solution  
 
5.[ADDRESS_696425] SR dose groups will be a Sham administration procedure + timolol eye drops 
BID . 
The site coordinator and designated staff will not  be masked to whether the patient received 
[ADDRESS_696426] SR or  the Sham administration procedure, but will 
be masked to the specific implant dose strength.  The patient and the remaining staff will be 
masked to the patient’s treatment assignment.  Efficacy IOP measurements will be masked by 
[CONTACT_2329] a 2-person reading met hod as described in Section 6.1.1 (for optional postoperative 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 42 GDD-TA-T-004 v2013.9 
 IOP measurements for patients with sickle cell disease or trait [or other hemoglobinopathies], 
see Section 8.4). 
The site staff who perform IOP readings will be  masked regarding the study eye (which eye 
received Bimatoprost SR or the Sham administration procedure), Bimatoprost SR dose 
strength, and the study treatments that are delivered in bottles.  Site personnel and patients 
will be instructed and reminded throughout the study not to discuss study medication 
assignments to ensure maintenance of the masking. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 43 GDD-TA-T-004 v2013.9 
 5.4 Treatment Allocation Ratio and Stratification 
Randomization to treatment groups will use a 1: 1:[ADDRESS_696427] SR (either 10 µg or 15 µg) plus vehicle eye drops, or a Sham 
administration procedure plus timolol eye drops, in the study eye.  Randomization will be 
stratified by [CONTACT_535383] 0 IOP ( ≤ 25 mm Hg or > 25 mm Hg). 
5.5 Method for Assignment to Treatment Groups/Randomization 
Prior to initiation of any study procedures, ea ch patient who provides informed consent will 
be assigned a subject number th at will serve as the patient’s identification number on all 
study documents. 
Eligible patients will be randomly assigned to 1 of 3 treatment groups in a 1:1:[ADDRESS_696428] SR 15 µg, or timolol.  The randomization 
will be stratified by [INVESTIGATOR_31975] H our 0 IOP (baseline study eye IOP ≤ 25 mm Hg or 
> 25 mm Hg). 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696429] SR in the study eye 
on Day 1, Week 16, and Week 32, in addition to using topi[INVESTIGATOR_535346] (1 drop 
BID).  They will receive timolol eye drops (1 drop BID) plus Sham administration in the 
fellow eye.  Patients randomized to the Control group will receive a Sham administration in 
both eyes on Day 1, Week 16, and Week 32, in addition to timolol eye drops (1 drop BID) in 
both eyes. 
5.6.1 Treatment Regimen/Dosage Adjustments  
Patients who have received nonstudy topi[INVESTIGATOR_15434]-lowering medication (prohibited before 
Week 52 unless required for safety reasons due to inadequate IOP cont rol and attested to by 
[CONTACT_093]) in a Bimatoprost SR study eye will receive Sham administration in that eye 
on the Bimatoprost SR repeat administration day(s).  Patients who have received nonstudy 
topi[INVESTIGATOR_15434]-lowering medication in a fellow eye or a Control Group study eye will continue 
to receive Sham administration in th at eye on the administration day(s). 
Patients who have received nonstudy IOP-lowering medication in both eyes will not undergo Bimatoprost SR administration or Sh am administration in either eye. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 45 GDD-TA-T-004 v2013.9 
 Patients who use nonstudy IOP-lowering medica tion (prohibited before Week 52 unless 
required for safety reasons due to inadequate IO P control and attested to by [CONTACT_093]) 
in only one eye will be followed for the duration of the study.  If used in both eyes, patients 
will be followed at minimum for [ADDRESS_696430] SR 
or Sham.  Patients using nonstudy IOP-loweri ng medications in both eyes prior to the 
Week 16 or Week 32 Administration Day will not  attend the administration visit(s), nor will 
they attend the Day 2, Days 4 and 8 (phone call), or 2-week visits (ie, Weeks 2, 18, and 34) 
following an administration.  They would continue the schedule at Week 22 or Week 38, as 
appropriate for the administration cycle. 
5.7 Storage of Study Medications/Treatments 
The study medication must be stored in a secu re area and administered only to patients 
entered into the clinical study, at no cost to  the patient, in accordance with the conditions 
specified in this protocol.  Only assigned study personnel, authorized  by [CONTACT_093], 
may have access to study medication.   
 
 
 
 
 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 46 GDD-TA-T-004 v2013.9 
 5.8 Preparation of Study Medications/Treatments  
Bimatoprost SR is loaded into the single use applicator during manuf acturing and is provided 
within the applicator as a sterile, finished product.  Study site personnel should notify 
Allergan or its designee immedi ately to advise of any situa tion in which the study medication 
is defective. 
5.[ADDRESS_696431] SR (or Sham) administration may be 
performed at an Ambulatory Surgical Center (A SC; free standing or hospi[INVESTIGATOR_78515]) or in the 
office setting (eg, in a proce dure room with an operating microscope).   
 
 
 
  A separate standard consent to have the 
procedure at an Ambulatory Surgical Center  may be required per the standard operating 
procedures at the facility. 
Sterile technique will be practiced at all times. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696432] to Allergan approval and training.  The study medication k it should be readily 
available during the procedure. 
5.9.4 Immediate Posttreatment Observation 
Following study treatment administration, the patient is allowed to sit upright and is kept for a minimum of 1 hour of observation.  The surge on will examine each of the patient’s eyes to 
ensure that the anterior chamber is form ed prior to the patient being released. 
 
 
 
Prior to leaving the site, patients should be inst ructed to contact [CONTACT_535384].  If the patient re ports having experienced 
adverse events, these should be re corded on the appropriate eCRF. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696433] SR or Sham administration. 
Note:  Patients with sickle cell disease or  trait (or other hemogl obinopathies) may undergo 
optional biomicroscopy and IOP examination in both eyes [ADDRESS_696434] SR 
administration (or Sham administration).  This optional IOP examination is for postoperative 
purposes only, and as such does not require a masked, 2-person reading method.  The IOP 
should be taken only once to avoid excessive postadministration (or Sham administration) manipulation of the eye, and should be take n by [CONTACT_093] (or other unmasked, 
qualified personnel).  This postadministration (o r Sham administration) examination may be 
performed using a Goldmann applanation tonome ter or a hand-held tonometer.  (See the 
Study Procedure Manual for details.) 
5.[ADDRESS_696435] SR dose strength to which 
they were randomized unless in th e investigator’s opi[INVESTIGATOR_535347].   
 
 
 
 
 
 
 
6. Response Measures and Summary  of Data Collection Methods 
 
 
6.1 Efficacy Measures 
6.1.1 Primary Efficacy Measure 
The primary efficacy measure, IOP, will be measured using a Goldmann applanation 
tonometer.  Examiners masked to the treatment assignment should perform all efficacy IOP 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696436] 2 measurements differ by > [ADDRESS_696437] 
2 measurements is > 1 mm Hg, the IOP for the given eye will be the median of the 3 readings. 
All Hour 0 IOP examinations should be scheduled at 08:00 ± [ADDRESS_696438] approximately the sa me Hour 0 time of day throughout the study.  
Hour 2 IOP examinations should occur 2 hours after the Hour 0 IOP exam.  The acceptable 
window for the Hour 2 IOP examination is ± 30 minutes. 
6.2 Safety Measures 
The following will be collected and recorded on the appropriate eCRF page(s):  
Adverse Events:  All adverse events, from the moment the patient signs the informed 
consent form, will be monitored and recorded in  the patient’s source documents.  All events 
will be reported to Allergan on an adverse event eCRF, including seriousness, severity, action 
taken and relationship to study drug.  If adverse events occur, the first concern will be the 
safety of the study patient. 
Weight and Height:  Weight will be measured in pounds (lb) or kilograms (kg) using a 
scale.  Height will be measured in inches (in)  or centimeters (cm).  Height and weight will be 
measured at screening as part of the demogra phic data; historical patient information and/or 
patient reports should not be used for either measurement.  
Vital signs:  Systolic and diastolic blood pressure a nd pulse rate will be measured after 
patients have been at rest (seated) for at least 5 minutes.  Body temperature will be measured 
orally (or with an infrared forehead thermometer) and recorded as °F or °C. 
Hematology, blood chemistry, and urinalysis:  Blood and urine samples will be collected 
for blood chemistry and hematology panels and urinalysis.   
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 50 GDD-TA-T-004 v2013.9 
 Pregnancy:  Females of childbearing potential will have pregnancy tests performed.  
Pregnancy test kits will be provided by [CONTACT_535385] a designated 
regional laboratory and will be administered according to the instructions provided with the 
tests.  
Measures of ocular safety include : 
Visual Acuity:  Visual acuity tests will be performed at  all scheduled visits except on any of 
the [ADDRESS_696439] refraction using Snellen equivalent with a logMar chart 
(see Protocol Procedure Manual) will be performed at Screening, Baseline, Weeks 12 and 52, 
and Month 20/Exit.  At all other visits, the visual acuity technician will use the last manifest 
refraction performed and determine the Snellen equivalent visual acuity using the logMar 
chart.  If there is a 2-line or more reduction in visual acuity from the last BCV A performed, a 
repeat manifest refraction in both eyes and BCV A will be performed.  
Macroscopic Iris Color Assessment:  Iris color will be assessed visually at each designated 
visit using the appropriate assessment guide (s ee the Protocol Procedure Manual for further 
details).  Macroscopic, binocular color photography will be performed at baseline to document iris color.  The baseline photograph pr intout from each patient will be used as a 
comparator to assess any change in iris color at subsequent visits.  A suspected change in iris 
color will be documented with a binocular color photograph at that visit.  A binocular color 
photograph will also be obtained at Week 52 and a final binocular color photograph will be obtained during the Month 20/Exit visit in all patients. 
Progressive changes in iris color will be photographed and compared to the last photograph 
taken. 
Macroscopic Conjunctival Hyperemia Assessment:   Macroscopic conjunctival hyperemia 
will be assessed using the appropriate Assessm ent Guide (see the Protocol Procedure Manual 
for further details). 
Bimatoprost SR
 Implant Assessment:  Using gonioscopy, the investigator will evaluate the 
Bimatoprost SR implant  and the inferior iridocorneal angle. 
Biomicroscopic Examination:  Biomicroscopic examinations will be performed using a slit 
lamp.  The examinations will include evaluation of the condition of the eyelids, conjunctiva, 
cornea, AC, iris/pupil, and lens.   
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 51 GDD-TA-T-004 v2013.9 
 Lens Assessment:  Biomicroscopic findings will be ev aluated for the presence and severity 
of nuclear, cortical, and posteri or subcapsular lens opacities.  See the Protocol Procedure 
Manual for further details. 
Gonioscopy : Gonioscopic examination for eligib ility at Screening (only) will be 
independently performed by 2 ophthalmologists as described in the Protocol Procedure 
Manual. The independent eligibility assessors should not share their assessments with each 
other until the assessment is recorded. The 2 ophthalmologists’ independent eligibility 
assessments must confirm patient eligibility for participation in the study. Subsequent 
gonioscopic examinations will be performed by [CONTACT_1704]. 
Optic Disc Examination:   The cup/disc ratio and presence of optic disc pathology will be 
determined using stereoscopic evaluation. Dilated Ophthalmosco pic Examination:  The stereoscopic fundus assessments should be 
conducted through a dilated pupil.  The examinations will include evaluation of the macula, 
vitreous, and retina.  
Optical Coherence Tomography (OCT):   OCT of the macula will be performed to assess 
macular edema.  The same instrument shoul d be used throughout the study for a given 
patient.  See the Protocol Procedure Manual for further details. 
Specular Microscopy:  Endothelial cell density will be a ssessed using specular microscopy 
performed on the central cornea at all sites.  The final qualification of  central endothelial cell 
density for study entry will be determined by [CONTACT_3433] e Reading Center.  Qual ification will remain 
valid for 1 year after Screening in patients who ar e not enrolled at the time of Screening, if in 
the investigator’s opi[INVESTIGATOR_535348] (eg, ocular surgery) during that time.  All additional specular microscopy images taken 
during the study will be assessed by [CONTACT_66322].  See the Protocol Procedure Manual 
for further details.  The same instrument should be used throughout the study for a given 
patient. 
Pachymetry:  Corneal thickness using ultrasound (contact) pachymetry will be performed on 
the central cornea.  The same instrument should be used throughout the study for a given 
patient.  Contact [CONTACT_535386] 2 IOP measurement.  
See the Protocol Procedure Manual for further details.  
Anterior Segment Optical Coherence Tomography (AS-OCT):   AS-OCT measurements 
will be performed at all sites and a Reading Center will be used to examine angle size for 
 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 inves
for fu
manu
desig
study
Visu a
perim
patie n
6.[ADDRESS_696440] o
proce
those
to thegan Confidenti a
stigational p u
urther detail s
uals is not a v
gnated Read i
y for a given 
al Field Ex a
metry (
).  The s a
nt. 
Ot
Ex
y evaluation
tudy whene v
nt, then an a
her and dis c
[ADDRESS_696441] medi c
or currently 
edures shoul
e stopped wi t
e screening val 
urposes.  Se e
s on the use 
vailable, a s u
ing Center f o
patient. 
amination:  
ame test met h
ther Mea s
xaminati o
s should be p
ver possible. 
attempt shou l
uss finding s
Medical Hi
Medical Hi s
cal history ( i
has) will be 
d have an a s
thin [ADDRESS_696442].  In 
uitable alter n
or use.  The 
Visual field 
hodology m u
sures (Op t
n Proced u
performed b
 If it is not p
ld be made t
s) for at leas t
story, Phy
story  
including al l
captured in 
ssociated m e
 prior to the 
recorded.  I n
[ADDRESS_696443] be used t
tional) 
ures, Test s
by [CONTACT_63931] i
possible to u
to have inve s
t 1 visit. 
ysical Exa m
 relevant co n
the patient s
edical histor y
screening v
n addition, aP
sition manu a
at the AS-O C
be approved b
ment should 
ns will be a s
throughout t
s, Equipm e
investigator /
use the sam e
stigators ov e
mination, 
nditions tha t
source docu m
y entry.  Cu r
visit and pro c
all previous mProtocol [ADDRESS_696444] u
ent, and T
/subinvestig a
e individual t
erlap (exam i
and Vital
t the patient 
ments.  All s
rrent medic a
cedures wit h
medications 24-092 Amend m
A-T-004 v2013Reading C e
specified in t
and the 
oughout the 
g automate d
udy for a gi v
Technique s
ator throug h
to follow th e
ine the patie n
l Signs  
has had in t h
surgical 
ations as wel
hin 90 days p
taken for O Ament 3 
.9 enter 
the 
d 
ven 
s  
hout 
e 
nt 
he 
l as 
prior 
AG 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 or OH
docu m
6.4.1
The p
the fo
heart /
lymp
only. 
6.4.1
The b
any i n
• 
• 
• 
6.4.[ADDRESS_696445] i
testin
6.4.3
A cen
any r
bloodgan Confidenti a
HT for at le a
ment page. 
 Ph 1.2
patient will b
ollowing sy s
/cardiovasc u
hatic; and s k
 Vi 1.3
below vital s
nvasive pro c
Pulse rat e
for a min i
30 secon d
Blood pr e
minimu m
be measu r
blood pre
Temperat u
(or with a
[ADDRESS_696446]).  
ick method a
ng if require d
[ADDRESS_696447] 3 months 
hysical E x
be examine d
stems:  gene r
ular; lungs; a
kin.  The pa t
ital Si gns 
signs will be
cedures. 
e (beats per m
imum of 5 m
ds (and mult i
essure (mm H
m of 5 minut e
red with a s p
ssure meas u
ure (°C/°F): 
an infrared f o
regnanc y 
lected from 
The urine t e
at all specifi
d by [CONTACT_535387] a
aborator y
ory (
) w
atory tests.  B
hematolog yprior to stu d
xaminatio n
d by [CONTACT_73290] d
ral appeara n
abdomen; n e
tient’s heigh t
 measured a
minute [bp m
minutes prio r
iplied by 2 t
Hg):  the pa t
es prior to m
phygmoma n
uring device )
 patients sh o
orehead the r
Testin g 
females of c
est for pregn
ed timepoin t
al institution
y Procedu r
will analyze 
Blood and u r
y, and urinal y
53 dy entry wil l
n 
d medical p e
nce; head, ey
eurologic; e x
t and weigh t
at all patient 
m]):  the pati e
r to measure m
o obtain bp m
tient should 
measurement .
nomete r (man
). 
ould be seat e
rmometer). 
childbearing 
ancy will b e
ts.  Serum t e
. 
res 
blood and u
rine sample s
ysis. P
l be recorde d
ersonnel for 
yes, ears, no s
xtremities; b a
t will be rec o
visits an d sh
ent should b e
ment.  Puls e
m). 
be resting i n
.  Systolic/d i
nual sphyg m
ed and the b
potential fo
e performed 
esting may b
urine speci m
s will be obt aProtocol 1920 2
GDD-T Ad on the ap p
any physic a
se, and thro a
ack; muscul
orded at the 
hould be rec o
e resting in a
e rate is the n
n a seated p o
iastolic bloo
momanomet e
body temper a
r pregnancy
at the site u t
be performe d
mens for this 
ained for th e24-092 Amend m
A-T-004 v2013propriate so u
al abnormali t
at; 
oskeletal; 
Screening v
orded prior t
a seated pos i
n counted ov e
osition for a 
d pressure w
er or autom a
ature taken o
y testing (uri n
tilizing the 
d instead of u
study; inclu
e analysis o f ment 3 
.9 urce 
ty of 
visit 
to 
ition 
er 
will 
ated 
orally 
ne 
urine 
ding 
f

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 Refe r
colle c
Labo
Aller
labor
even t
Evalu
local 
6.4.3
Hem a
(HbA
conc e
coun t
bands
6.4.3
Serum
aspar
direc t
total 
6.4.3
Urine
ester a
(WB C
6.[ADDRESS_696448] r e
rgan or its d e
ratory result s
ts should be 
uation and m
site practic e
 H 3.1
atology will 
A1c), mean c
entration ( M
t, RBC mor p
s, lymphoc y
 Se 3.2
m chemistr y
rtate transa m
t bilirubin, g
bilirubin, to t
 Ur 3.3
e will be an a
ase, nitrite, p
Cs, RBCs, c
Otal 
tral Laborat o
ipment proc
esults will b e
esignee.  Th e
s for any ad v
reflected o n
management 
e. 
ematolo gy
be measure d
corpuscular h
MCHC), mea n
phology, tot a
ytes, monoc y
erum Che m
 will includ e
minase (AST )
glucose, indi
tal choleste r
rinalysis  
alyzed for cl a
pH, protein, 
asts, bacteri
ther Stud yory Manual f
edures. 
e forwarded 
e investigat o
verse events .
n an adverse 
of abnorma l
y  
d and inclu d
hemoglobin 
n corpuscul a
al white blo o
ytes, basoph i
mistry  
e albumin, a l
), bicarbona t
rect bilirubi n
rol, total pro t
arity, color, b
specific gra v
a, crystals, a
y Supplie s
54 for further d e
from the ce
or or qualifi e
.  Laborator y
event eCRF
l laboratory 
des hematoc r
(MCH), me a
ar volume ( M
od cell (WB C
ils, and eosi n
lkaline phos
te, calcium, 
n, magnesiu
tein, urea ni t
bilirubin, bl o
vity, urobili n
and epi[INVESTIGATOR_535349] a
s P
etails regar d
ntral labora t
ed site perso n
y test result s
F page. 
results sho u
rit, hemoglo b
an corpusc u
MCV), plate l
C) count an d
nophils). 
sphatase, ala n
chloride, cr e
um, phospho r
trogen, and u
ood, glucos e
nogen, and m
al cells). Protocol [ADDRESS_696449] r e
s that repres e
uld be condu c
bin, glycate d
ular hemogl o
lets, red blo o
d differentia l
nine transa m
eatinine, cre
rous, potass i
uric acid. 
e, ketones, l e
microscopic 24-092 Amend m
A-T-004 v2013laboratory 
tudy site an d
eview all 
ent adverse 
cted accordi
d hemoglob i
obin 
od cell (RB C
l (neutrophi l
minase (AL T
atine kinase
ium, sodiu m
eukocyte 
sediment ment 3 
.9 d to 
ing to 
in, 
C) 
ls, 
T), 
, 
m, 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696450] completed or prematurely discontinued before the Week 12 visit.  Similarly, the 
database will be locked after all patients ha ve completed or prematur ely discontinued before 
Week 52 and Month 20/Exit.  Analyses will be pe rformed after each lock.  Prior to the first 
database lock a detailed analysis plan will be finalized.  To maintain the integrity of the 
ongoing study, Allergan study personnel who ar e directly involved in data handling and 
supporting the trial (such as th e clinical study team) will re main masked to treatment 
assignment of individual patients during the study. To avoid potential data unmasking 
between locks and to protect trial integrity,  study statistical personnel who have been 
unmasked after each lock will no longer be involved directly in any ongoing masked study 
conduct. Another statistician, who is still masked to study treatment, will assume these 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 56 GDD-TA-T-004 v2013.9 
 responsibilities until the next lock. Unmasked data handling and appropriate data and results 
access will be specified prior to each lock. 
Efficacy analyses specific for the US FDA (Division of Transplant and Ophthalmology 
Products) review are de scribed in Section 7.6. 
The details of all analyses will be provided in the analysis plan. 
7.1 Analysis Populations 
The intent-to-treat population (ITT) is defined as  all randomized patients and will be used for 
demographic and efficacy analyses.  The per pr otocol (PP) population will consist of the 
subset of the ITT population with no protocol deviations affecting the primary efficacy analysis and will be used to confirm the primar y efficacy analysis.  A list of patients excluded 
from the PP population will be finalized prior to database lock.  The safety population is 
defined as all patients who received study drug treatment and will be used for safety 
analyses.  Analyses in the ITT population will be based on the treatment to which a patient 
was randomized, and analyses in both PP and safety populations will be based on the actual treatment a patient received. 
7.2 Collection and Derivation of Pr imary and Secondary Efficacy 
Assessments 
The primary efficacy measurement is IOP, which will be measured in each eye using the 
Goldmann applanation tonometer.  Two consecutive measurements will be taken for each 
eye.  If these 2 measurements differ by > [ADDRESS_696451] measurement is 
required but only 2 measurements are obtained, then the IOP value for a given eye is the 
average of the 2 measurements.  If 3 measuremen ts are required (ie, the first 2 measurements 
differ by > 1 mm Hg) and obtained, then the IOP value for the given eye is the median of the 
3 measurements.  If, for any reason, only a si ngle measurement is obtained, then this 
measurement will be used as the IOP value. 
To avoid confounding of efficacy data, IOP measur ements obtained after initiating the use of 
nonstudy IOP-lowering medication in an eye will  be excluded from the calculation of the 
summary statistics and the statistical analyses fo r that eye but raw values will be presented in 
the listings. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 57 GDD-TA-T-004 v2013.9 
 7.2.1 Primary Efficacy Variable 
The primary efficacy variable is the study eye time-matched IOP change from baseline 
(follow-up minus time-matched baseline) at each hour evaluated (Hours 0 and 2). 
7.2.[ADDRESS_696452] SR dose strength and the 
timolol group for each hour (Hours 0 and 2) using the ITT population.  The comparisons at 
Week [ADDRESS_696453] SR 
dose strength and timolol at each hour of Week 12 are: 
• Null hypothesis:  the difference in mean IO P change from baseline between the given 
Bimatoprost SR dose strength and timolol  (Bimatoprost SR minus timolol) is 
> 1.5 mm Hg. 
• Alternative hypothesis:  the difference (B imatoprost SR minus timolol) in mean IOP 
change from baseline between the given Bi matoprost SR dose strength and timolol is 
≤ 1.5 mm Hg. 
Intraocular pressure change from baseline will be analyzed using a mixed-effects model 
repeated measures (MMRM) approach.  The model will include IOP time-matched change 
from baseline as the response variable and treat ment, timepoint (Hours 0 and 2 at each visit 
of Weeks 2, 6, and 12), treatment-by-timepoint in teraction, and baseline IOP stratification as 
fixed effects. Unstructured covariance matrix w ill be used for repeated measures on the same 
patient; if the model with unstructured cova riance matrix fails to converge, multiple 
imputation (MI) will be implemented befo re MMRM.  The details of the model 
specifications will be provided in the analysis plan. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696454] SR dose 
strength and timolol (Bimatoprost SR minus  timolol) and the corresponding 2-sided 95% 
confidence interval will be provided for each hour (Hours 0 and 2) at each visit.  The formal 
noninferiority test will be performed at W eek [ADDRESS_696455] SR 15 µg (or 10 µg) will be declared 
noninferior to timolol if the upper limit of the 95% confiden ce interval is ≤ 1.[ADDRESS_696456] the no-difference null hypothesis will be perf ormed at scheduled visits (Weeks 2, 6, and 
12) and hours for (1) IOP and (2) time-matched IOP change from baseline. 
The analysis of time-matched IOP change from baseline utilizes the identical model as that 
described for the prim ary analysis in Section 7.3.1 with the same 2-sided 95% confidence 
intervals constructed at each hour and each visit for the mean difference between each 
Bimatoprost SR dose strength and timolol (Bim atoprost SR minus timolol).  An upper 95% 
confidence limit of the mean difference that is  less than zero corres ponds to a significant 
difference in favor of the given Bimatoprost SR dose strength for the given timepoint. 
Each Bimatoprost SR dose strength that de monstrates the following at all scheduled 
timepoints within the 12-week period (at Hours 0 and 2 at Weeks 2, 6, and 12) will be 
considered superior to timolol: 
• The upper 95% confidence limit of the mean difference is less than zero (ie, a 
significant difference in favor of the given Bimatoprost SR dose strength) 
The analysis of IOP will be similarly performe d as described above with IOP replacing time-
matched IOP change from baseline in the analysis model. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 59 GDD-TA-T-004 v2013.9 
 7.3.3 Other Efficacy Analyses 
7.3.4 Safety Analyses 
The Medical Dictionary for Regulatory Activitie s (MedDRA) nomenclature will be used to 
code adverse events.  Adverse events will be coded from the verbatim text into preferred term 
and system organ class (SOC).  The number and percent of patients reporting treatment 
emergent adverse events will be tabulated based on the primary SOC and preferred terms.  
Summary tables will be generated for all advers e events regardless of causality as well as 
treatment-related adverse events for the entire study and by [CONTACT_224360]. 
Other safety variables include vital signs (blood pressure, pulse  rate, and temperature) and 
pregnancy test results.  Ocular safety will be  evaluated through assessment of visual acuity 
and visual field; evaluation of  macroscopic bulbar conjunctiv al hyperemia and iris color; 
assessment of endothelial cell density a nd corneal thickness; IOP measurement, 
biomicroscopic and ophthalmoscopic examinations  (including gonioscopy with Bimatoprost 
SR implant assessment, optic disc examinati on and dilated fundus examination); and OCT of 
the macula.  
Ocular adverse events and sa fety variables will be tabul ated by [CONTACT_535388], and nonocul ar safety variables will be summarized by 
[CONTACT_4676].  A separate summary will be provided for safety events occurring after nonstudy 
IOP-lowering medication has been initiated. 
7.[ADDRESS_696457] either completed or 
exited from the targeted visit. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696458] SR dose strength and timolol for each hour 
(Hours 0 and 2) at Weeks 2, 6, and 12. 
The null and alternative hypotheses for the co mparison between a given Bimatoprost SR 
dose strength and timolol for each hour at each visit are: 
• The null hypothesis is that the difference in  mean IOP between the given Bimatoprost 
SR dose strength and timolol (Bimatoprost SR minus timolol) is > 1.5 mm Hg. 
• The alternative hypothesis is that the diff erence (Bimatoprost SR minus timolol) in 
mean IOP between the given Bimatopros t SR dose strength and timolol is 
≤ 1.[ADDRESS_696459] SR dose strength and timolol a nd the corresponding 2-sided 95% confidence 
interval will be provided for each hour (Hours 0 a nd 2) and each visit (Weeks 2, 6, and 12).  
A gatekeepi[INVESTIGATOR_535350] I error rate at the 0.[ADDRESS_696460] SR dose strength that shows n oninferiority to timolol at all 6 timepoints 
with a 1.5 mm Hg margin (ie, the upper limit of the 95% confidence interval is ≤ 1.5 mm Hg) 
will be declared clinically noninferior to ti molol if the upper limit of the 95% confidence 
interval is ≤ 1.[ADDRESS_696461] SR dose strength which de monstrates efficacy (clinical noninferiority) 
as described in the primary efficacy analyses, secondary efficacy analyses comparing the 
Bimatoprost SR dose strength and timolol to test the no-difference null hypothesis will be 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 61 GDD-TA-T-004 v2013.9 
 performed at scheduled visits (Weeks 2, 6, and 12) and hours for IOP.  A gatekeepi[INVESTIGATOR_535351] t ype I error rate at the 0.05 level within each 
dose strength; the specific sequence of the te sts will be provided in the analysis plan. 
Other Efficacy Analyses 
7.[ADDRESS_696462] with α = 0.[ADDRESS_696463] SR 10 µg 
and timolol is -0.25 mm Hg (ie, Bimatoprost SR  10 µg is 0.25 mm Hg better in IOP-lowering 
than timolol) at Weeks [ADDRESS_696464] correlati on of 0.6.  It was also assumed that the 
efficacy (IOP-lowering effect) of Bimatoprost SR [ADDRESS_696465] SR 
10 µg by 0.25 mm Hg at each timepoint (Hours 0 and 2).  These assumptions were made at 
the study design phase based on the data obtained from the ongoing clinical study 
192024-041D.  Based on simulations, a sample size of 540 patients (180 per group) would 
provide approximately 95% and 81% power to show noninferiority (NI) of Bimatoprost SR 
[ADDRESS_696466] SR 10 µg, respectively, to  timolol at all 6 scheduled timepoints based 
on an NI margin of 1.5 mm Hg and at 3 or more timepoints based on an NI margin of 
1.0 mm Hg.  Assuming a premature discontinua tion rate of 10% with in 12 weeks (before 
primary database lock), approximately 600 patient s (200 per group) were to be enrolled into 
this study. 
As part of ongoing centralized data monitoring of masked study data, some of the initial 
assumptions used for sample size calculation have been revisited. The rate of discontinued or 
rescued patients in the first 12 weeks is approximately 5%, which was less than the rate of 
10% assumed at the study design phase. Furthe rmore, the masked common IOP variability 
(pooled standard deviation across treatments and timepoints) is approximately 3.8 mm Hg, 
which was also less than the assumed 4.0 mm Hg at the study design phase. With the updated 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696467] devi ation of 3.8 mm Hg, a sample size of 
486 patients (162 per group) would provide appr oximately 95.1% and 83.5% power to show 
NI of Bimatoprost SR [ADDRESS_696468] SR 10 µg, respectively, to timolol at all 
6 scheduled timepoints based on an NI margin of 1.5 mm Hg; and at 3 or more timepoints 
based on an NI margin of 1.0 mm Hg. With the updated premature discontinuation or rescue 
rate of 5% within 12 weeks, approximately 510 patients (170 per group) are to be enrolled 
into this study. 
8. Study Visit Schedule and Procedures 
Patients who complete the entire study without receiving nonstudy IOP-lowering medication will have a minimum of [ADDRESS_696469] SR or Sham administration (Day 1), visit on Day 2, phone calls on Days 4 and 8, and visits on Weeks 2, 6, 12, and 15 (which is the visit prior to the next 
administration day).  Additional treatment period visits occur through Week 52 and extended follow-up continues into Months 14, 16, 18, and 20/exit. 
The study visits should adhere as closely as possible to the schedule show n in Table 2  
through Table 6 .  See Figure 1 for a flowchart of patient participation.  
8.1 Patient Entry Procedures  
8.1.1 Overview of Entry Procedures 
Prospective patients as defined by [CONTACT_3433] e criteria in Sections 4.3 and 4.4 (inclusion/exclusion 
criteria) will be considered for entry into this study.   
8.1.[ADDRESS_696470] also give authorization (US only), data protection consent (Europe only), and other 
written documentation in accordance with th e relevant country and local privacy 
requirements (where applicable) prior to any stud y-related procedures or change in treatment. 
Each patient who provides informed consent wi ll be assigned a subject number that will be 
used on patient documentation throughout the study. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696471] provide informed consent prior to beginning any drug washout for the 
purposes of inclusion in this study.  Patient s currently being treated with IOP-lowering 
medication(s) in either eye will begin washout of these medication(s) following completion 
of the screening procedures.  The Screening and Washout periods may not be concurrent.  
The Washout period will be up to 42 days  depending on the minimum washout period 
schedule below. 
If, after initial washout, the IOP does not meet en try criteria and the investigator believes this 
is due to inadequate washout, if time remain s in the Washout period, he/she may perform 
additional washout, as long as the total Washout period does not exceed 42 days. 
For patients undergoing a washout, interim safet
y evaluation(s) of IOP at some time during 
the washout period may be performed at  the discretion of the investigator. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 64 GDD-TA-T-004 v2013.9 
 Note:  Medications should only be discontinued (w ashed out) if the investigator feels that it 
is safe and appropriate, and if the patient is  willing to discontinue the medication for the 
duration of the study.  If the medication cannot be  discontinued, then the patient will not be 
eligible for study entry. 
8.3 Procedures for Final Study Entry 
The results from the screening ocular and physical examinations, and laboratory tests 
(hematology/blood chemistry/urinalysis) must be evaluated and determined to be acceptable 
to the investigator prior to the patient’s entry into the study.  If repeat laboratory tests are 
done, the results must be reviewed prior to study treatment initiation on Day 1.  Reading 
Center qualification of endothelial cell density  must be confirmed by [CONTACT_535372].  
After confirmation of eligibility on Day 1, IV/WRS is contact[CONTACT_535389].  However, this contact [CONTACT_535390].  See Section 5.5 for the method for assignment to treatment groups/randomization. 
A patient is considered to have enrolled in the study at the time of the first study treatment 
administration (or Sham). 
8.[ADDRESS_696472] of proced ures for each scheduled visit.   
 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696473] been obtained (as described in 
Section 8.1.2), the procedures listed below are done .  Intraocular pressure measurements 
must be performed in one day; however, othe r procedures (eg, postdilation and imaging 
procedures) may be performed on a different da y as long as the screening procedures are 
completed within a 28-day period.  Perform pupil dilation/diagnostic procedures after the 
completion of the final IOP measuremen t of the day or on a different day. 
• Collection of demographic data 
• Collection of medical and ophthalmic history 
• Collection of adverse events 
• Collection of concomitant medications and procedures 
• Physical examination 
• Vital signs 
• Collection of blood and urine samples 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696474] been completed. 
8.4.2 Baseline Visit 
The Baseline visit occurs afte r the Washout period has been completed.  Final Reading 
Center confirmation of central endothelial cell de nsity should be receiv ed by [CONTACT_535391].  Baseline visit procedures, excluding IOP measurements (which must be 
performed in 1 day), can be performed over a 3- day period; all must be completed by [CONTACT_535392].  Perform pup il dilation/diagnostic procedures after the 
completion of the final IOP measuremen t of the day or on a different day. 
• Collection of medical and ophthalmic hist ory (changes since the Screening visit) 
• Collection of adverse events 
• Collection of concomitant medications and procedures 
• Vital signs  
• Pregnancy test for females of childbear ing potential (as defined in Section 4.5.3) 

 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
8.4.3
The f
• 
• 
• 
• 
• gan Confidenti a
[ADDRESS_696475] eal 
reatment P
ycle 1:  D a
ocedures ar e
n of adverse 
n of conco m
ns  
eligibility 
er assigned sPeriod 
ay 1 Adm i
e performed 
events 
mitant medic a
study treat m
67 inistratio n
on the day o
ations and p r
ment P
n Day 
of study tre a
rocedures Protocol 1920 2
GDD-T Aatment admi n24-092 Amend m
A-T-004 v2013nistration: ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
On D
• 
• 
• gan Confidenti a
 Cy 3.2
Day 2 after s t
Collectio n
Collectio n
Vital sig nal 
ycle 1:  D a
tudy treatm e
n of adverse 
n of conco m
ns ay [ADDRESS_696476] r
events 
mitant medic a
68 ration, the f o
ations and p rP
ollowing pro
rocedures Protocol 1920 2
GDD-T Aocedures are 24-092 Amend m
A-T-004 v2013performed:ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• gan Confidenti a
 Cy 3.5
following pr
Collectio n
Collectio n
Vital sig nal 
ycle 1:  W
ocedures ar e
n of adverse 
n of conco m
ns Week 6  
e performed 
events 
mitant medic a
69 at Week 6 ( ±
ations and p rP
±4 days): 
rocedures Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• 
8.4.3
The f
• 
• 
• gan Confidenti a
 Cy 3.6
following pr
Collectio n
Collectio n
Vital sig n
 Cy 3.7
following pr
Collectio n
Collectio n
Vital sig nal 
ycle 1:  W
ocedures ar e
n of adverse 
n of conco m
ns 
ycle 1:  W
ocedures ar e
n of adverse 
n of conco m
ns Week 12  
e performed 
events 
mitant me dica
Week 15  
e performed 
events 
mitant medic a
70 at Week 12 
ations and p r
at Week 15 
ations and p rP
(± 4 days):
rocedures 
(± 4 days):
rocedures Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• 
• gan Confidenti a
 Cy 3.[ADDRESS_696477] eal 
ycle 2:  W
ocedures ar e
n of adverse 
n of conco m
ns  
er assigned sWeek 16 A d
e performed 
events 
mitant medic a
study treat m
71 dministrat i
at Week 16 
ations and p r
ment P
ion Da y 
(-2 to +4 d a
rocedures Protocol 1920 2
GDD-T Aays): 24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
On D
perfo
• 
• 
• 
8.4.3
On D
conta
• 
• 
8.4.3
The f
• 
• 
• gan Confidenti a
 Cy 3.9
Day 2 after t h
ormed: 
Collectio n
Collectio n
Vital sig n
 Cy 3.10
Day 4 and D a
acted by [CONTACT_21060] p
Collectio n
Collectio n
 Cy 3.11
following pr
Collectio n
Collectio n
Vital sig nal 
ycle 2:  D a
he second st u
n of adverse 
n of conco m
ns 
ycle 2:  D a
ay 8 after th e
phone to co l
n of adverse 
n of conco m
ycle 2:  W
ocedures ar e
n of adverse 
n of conco m
ns ay [ADDRESS_696478] the foll o
events 
mitant medic a
Week 18  
e performed 
events 
mitant medic a
72 nt administr a
ations and p r
Day 8 (Ph o
cle administ r
owing: 
ations and p r
at Week 18 
ations and p rP
ation, the fo l
rocedures 
one Calls)
ration proce d
rocedures 
(±4 days): 
rocedures Protocol 1920 2
GDD-T Allowing pro c
dure, the pa t24-092 Amend m
A-T-004 v2013cedures are 
tient will be ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• 
8.4.3
The f
• gan Confidenti a
 Cy 3.12
following pr
Collectio n
Collectio n
Vital sig n
 Cy 3.13
following pr
Collectio nal 
ycle 2:  W
ocedures ar e
n of adverse 
n of conco m
ns 
ycle 2:  W
ocedures ar e
n of adverse Week 22  
e performed 
events 
mitant medic a
Week 28  
e performed 
events 
73 at Week 22 
ations and p r
at Week 28 P
(±4 days): 
rocedures 
(±4 days): Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 • 
• 
8.4.3
The f
• 
• 
• gan Confidenti a
Collectio n
Vital sig n
 Cy 3.14
following pr
Collectio n
Collectio n
Vital sig nal 
n of conco m
ns 
ycle 2:  W
ocedures ar e
n of adverse 
n of conco m
ns mitant medic a
Week 31  
e performed 
events 
mitant medic a
74 ations and p r
at Week 31 
ations and p rP
rocedures 
(± 4 days):
rocedures Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• 
• gan Confidenti a
 Cy 3.[ADDRESS_696479] eal 
ycle 3:  W
ocedures ar e
n of adverse 
n of conco m
ns  
er assigned sWeek 32 A d
e performed 
events 
mitant medic a
study treat m
75 dministrat i
at Week 32 
ations and p r
ment P
ion Da y 
(-2 to + 4 d a
rocedures Protocol 1920 2
GDD-T Aays): 24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
On D
perfo
• 
• 
• 
8.4.3
On D
conta
• 
• 
8.4.3
The f
• 
• 
• gan Confidenti a
 Cy 3.16
Day 2 after t h
ormed: 
Collectio n
Collectio n
Vital sig n
 Cy 3.17
Day 4 and D a
acted by [CONTACT_21060] p
Collectio n
Collectio n
 Cy 3.18
following pr
Collectio n
Collectio n
Vital sig nal 
ycle 3:  D a
he third stud y
n of adverse 
n of conco m
ns 
ycle 3:  D a
ay 8 after th e
phone to co l
n of adverse 
n of conco m
ycle 3:  W
ocedu res are
n of adverse 
n of conco m
ns ay [ADDRESS_696480] the foll o
events 
mitant medic a
Week 34  
e performed 
events 
mitant medic a
76 administrati o
ations and p r
Day 8 (Ph o
administrat i
owing: 
ations and p r
at Week 34 
ations and p rP
on, the foll o
rocedures 
one Calls)
ion procedu r
rocedures 
(± 4 days):
rocedures Protocol 1920 2
GDD-T Aowing proce d
re, the patie n24-092 Amend m
A-T-004 v2013dures are 
nt will be ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• 
8.4.3
The f
• gan Confidenti a
 Cy 3.19
following pr
Collectio n
Collectio n
Vital sig n
 Cy 3.20
following pr
Collectio nal 
ycle 3:  W
ocedures ar e
n of adverse 
n of conco m
ns 
ycle 3:  W
ocedures ar e
n of adverse Week 38  
e performed 
events 
mitant medic a
Week 44  
e performed 
events 
77 at Week 38 
ations and p r
at Week 44 P
(±4 days): 
rocedures 
(± 4 days):Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 • 
• 
8.4.3
The f
• 
• 
• gan Confidenti a
Collectio n
Vital sig n
 Cy 3.21
following pr
Collectio n
Collectio n
Vital sig nal 
n of conco m
ns 
ycle 3:  W
ocedures ar e
n of adverse 
n of conco m
ns mitant medic a
Week 48  
e performed 
events 
mitant medic a
78 ations and p r
at Week 48 
ations and p rP
rocedures 
(± 4 days):
rocedures Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.3
The f
• 
• 
• gan Confidenti a
 Cy 3.22
following pr
Collectio n
Collectio n
Vital sig nal 
ycle 3:  W
ocedures ar e
n of adverse 
n of conco m
ns Week 52  
e performed 
events 
mitant medic a
79 at Week 52 
ations and p rP
(± 7 days):
rocedures Protocol 1920 2
GDD-T A24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.4
8.4.4
The f
• 
• 
• 
8.4.4
The f
• 
• 
• gan Confidenti a
4 E
 M 4.1
following pr
Collectio n
Collectio n
Vital sig n
 M 4.2
following pr
Collectio n
Collectio n
Vital sig nal 
xtended F
Month 14  
ocedures ar e
n of adverse 
n of conco m
ns 
Month 16  
ocedures ar e
n of adverse 
n of conco m
ns Follow Up
e performed 
events 
mitant medic a
e performed 
events 
mitant medic a
80  
at the Mont h
ations and p r
at the Mont h
ations and p rP
h 14 (± 14 d
rocedures 
h 16 (± 14 d
rocedures Protocol 1920 2
GDD-T Adays) visit: 
days) visit: 24-092 Amend m
A-T-004 v2013ment 3 
.9 

 
 
Approval Date :  
 05-Jun-2018Aller g
 
 
 8.4.4
The f
• 
• 
• 
8.4.4
The fgan Confidenti a
 M 4.3
following pr
Collectio n
Collectio n
Vital sig n
 M 4.4
following pral 
Month 18  
ocedures ar e
n of adverse 
n of conco m
ns 
Month 20/ E
ocedures ar ee performed 
events 
mitant medic a
Exit 
e performed 
81 at the Mont h
ations and p r
at the Mont hP
h 18 (± 14 d
rocedures 
h 20 (± 14 dProtocol 1920 2
GDD-T Adays) visit: 
days) visit o r24-092 Amend m
A-T-004 v2013r at early ex iment 3 
.9 it: 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 82 GDD-TA-T-004 v2013.9 
 • Collection of adverse events 
• Collection of concomitant medications and procedures 
• Vital signs 
• Pregnancy test for females of childbearing potential 
8.5 Instructions for the Patients 
Patients should be instructed to strictly follow the study visit schedule and to report all 
changes in their condition to the investigative site. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696481] the study site if they are 
experiencing any difficulties during their study participation. 
Patients should keep the study medication bottles  in the original kit that was provided and 
return the bottles to the designa ted (unmasked) site staff.  Patients should be instructed that 
bottles of provided medications should only be used for [ADDRESS_696482] be able to adhere to the study vi sit schedule; appropriate inclusion, exclusion, 
and treatment criteria; permitted and prohibited medication criteria; and testing parameters as 
described in the protocol.  At each study visit, patients will be asked if they have used their 
study-provided eye drops as instructed and whether they have used any concomitant 
medications/therapi[INVESTIGATOR_535352]. 
Patients should be scheduled for study visits as closely to the day specified in the visit 
schedule as possible. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696483] SR or Sham administration at which time they should complete the Month 20/Exit visit procedures. 
Notification of early patient discontinuation from the study a nd the reason for discontinuation 
will be made to the sponsor and will be clearly documented on the appropriate eCRF. 
When patients exit before Month 20, the site  should complete all procedures for the 
Month 20/Exit visit at the patient’s last visit. 
8.[ADDRESS_696484] administration (or Sham), failure  to undergo an Administration Day visit does 
not indicate total withdrawal from the study .  Patients who have received nonstudy 
IOP-lowering medication in only one eye will co ntinue through the duration of the study.  
Patients who have received nonstudy IOP-loweri ng medication in both eyes, or patients who 
do not undergo Cycle 2 or 3 (or both) Administration Visits, will still be followed for 
[ADDRESS_696485] SR or Sh am administration for safety reasons.  These 
patients are eligible for Early Discontinuati on (Early Exit) as described in Section 8.8, above.  
The investigator should consider withdrawing a patient from the study early if any of the 
following criteria are met: 
• Patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_8574], compromises the patie nt’s ability to participate in the study 
• Patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_8574], compromises the patie nt’s ability to participate in the study 
• Patient is unwilling or unable to continue to comply with study procedures 
• Patient is unwilling or unable to continue in the study 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 85 GDD-TA-T-004 v2013.9 
 If a patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_13046], would put the patient at an  unacceptable medical risk by [CONTACT_535393], the patient will be withdrawn from the study. 
Whenever possible, the decision to withdraw  a patient from the study or study treatment 
should be discussed with Allergan. 
8.10 Study Termination 
The study may be stopped at his/he r study site at any time by [CONTACT_535394].  Allergan 
may stop the study (and/or the study site) for any reason with appropriate notification. 
9. Adverse Events  
Adverse events occurring during the study will be recorded on an adverse event eCRF.  If 
adverse events occur, the first concern w ill be the safety of the study participants. 
9.[ADDRESS_696486] a causal 
relationship with this treatment.  An advers e event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), sympto m, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.  In additi on, during the screening period, adverse events 
will be assessed regardless of the administration of a pharmaceutical product. 
Note:  Adverse events must be collected once in formed consent has been obtained, regardless 
of whether or not the patient ha s been administered study drug. 
Progression of treatment indicati on including new or worsening of  anticipated clinical signs 
or symptoms, which are collected as clinical efficacy variables and assessed as unequivocally 
associated with the disease progression and /o r lack of efficacy, should NOT be reported as 
adverse events unless the disease progression is greater than antic ipated in the natural course 
of the disease. Adverse events will be assessed, documented, and recorded in the CRF throughout the study 
(ie, after informed consent has been obtained).  At each visit, the investigator will begin by 
 
 
[CONTACT_535395] :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 86 GDD-TA-T-004 v2013.9 
 querying for adverse events by [CONTACT_535396] a general, nondirected question such as 
“How have you been feeling since the last visit?”  Directed questioning and examination will 
then be done as appropriate.  All reported  adverse events will be documented on the 
appropriate case report form. 
9.1.2 Serious Adverse Event 
A serious adverse event is any adverse event oc curring at any dose that results in any of the 
following outcomes:  death, a life-threatening adverse event, inpatient hospi[INVESTIGATOR_249589], a persistent or signifi cant disability/in capacity, or a 
congenital anomaly/birth defect.  Important medi cal events that may not result in death, be 
life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse event when, 
based upon appropriate medical judgment, they may jeopardize the patient or subject and 
may require medical or surgical intervention to  prevent one of the outcomes listed in this 
definition.  (See Section 9.3 for procedures for reporting a serious adverse event.) 
Allergan considers all cancer adverse events as serious adverse events.  In addition, Allergan 
considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
Preplanned surgeries or procedures for pre- existing, known medical conditions for which a 
patient requires hospi[INVESTIGATOR_249590] a serious adverse event. 
Any preplanned surgery or procedure should be clearly documented in the site source 
documents by [CONTACT_249617]’s entry into the 
study.  If it has not been documented at the time of the patient’s entry into the study, then it 
should be documented as a serious ad verse event and reported to Allergan. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696487] be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated. 
Moderate Discomfort enough to cause interference with usual activity. 
Severe Incapacitating with inability to work or do usual activity. Not applicable In some cases, an advers e event may be an ‘all or nothing’ finding 
which cannot be graded. 
 
9.1.4 Relationship to Study Drug or Study Procedure 
A determination will be made of the relations hip (if any) between an adverse event and the 
study drug or study procedure, as applicable.  A causal relationship is present if a 
determination is made that there is a reasonable possibility that the adverse event may have 
been caused by [CONTACT_335851]. 
If an adverse event is deemed related to st udy treatment, the investigator will be asked to 
further delineate whether the adverse event wa s related to the administration procedure 
(versus the study medication). Note:  A study procedure occurring during th e Screening/Baseline period can include a 
washout of medication or introduction of a r un-in medication or study required diagnostic 
procedure. 
9.[ADDRESS_696488] be recorded on the appropriate case report form. 
All adverse events that are drug- related and unexpected (not listed as treatment-related in the 
current Investigator's Brochure) must be re ported to the governi ng Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) as required by [CONTACT_1201]/IEC, local 
regulations, and the governing he alth authorities.  Any adverse event that is marked 
“ongoing” at the exit visit must be followed up as appropriate. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 88 GDD-TA-T-004 v2013.9 
 9.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed 
consent) and for at least [ADDRESS_696489] be reported to Allergan (or Agen t of Allergan)  
  All patients with a serious 
adverse event must be followed up and the outco mes reported.  The investigator must supply 
the sponsor and the IRB/IEC with any additional requested information (eg, autopsy reports 
and discharge summaries). 
In the event of a serious advers e event, the investigator must: 
1. Notify Allergan immediately  
 
 
2. Obtain and 
maintain in his/her files all pe rtinent medical records, information, and 
medical judgments from colleagues who assist ed in the treatment and follow-up of the 
patient. 
3. Provide Allergan with a complete, written description of the adverse event(s) on the 
serious adverse event form describing the event chronologically, including any treatment 
given (eg, medications administered, procedur es performed) for the adverse event(s).  
Summarize relevant clinical information abou t the event:  signs, symptoms, diagnosis, 
clinical course and relevant clinical laboratory tests, etc.   Include any additional or 
alternative explanation(s) for the causality which includes a statement as to whether the 
event was or was not related to th e use of the investigational drug. 
4. Promptly inform the governing IRB/IEC of th e serious adverse even t as required by [CONTACT_5040]/IEC, local regulations, and th e governing health  authorities. 
9.4 Procedures for Unmasking of Study Medication 
When necessary for the safety and proper trea tment of the patient, the investigator can 
unmask the patient’s treatment assignment to determine which treatment has been assigned 
and institute appropriate follow-up care.   
 
 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696490] ance with the applicable  Good Clinical Practice 
(GCP) regulations and guidelines, eg, the In ternational Conference on Harmonisation (ICH) 
Guideline on GCP. 
10.1 Protection of Human Subjects 
10.1.1  Compliance with Informed Co nsent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations 
Written informed consent is to be obtained from each patient prior to any study-related 
activities or procedures in the study, and/or from the pa tient's legally authorized 
representative.  If the patient is under the le gal age of consent, the consent form must be 
signed by [CONTACT_535397] w ith the relevant country and 
local regulatory requirements.  
There are special situations in which oral informed consent may be taken.  Approval to utilize 
oral consent procedures and in structions on how to properly ob tain oral informed consent 
must be obtained from Allergan personnel. 
10.1.2  Compliance With IRB or IEC Regulations 
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations.  The inves tigator must obtain a pproval from a properly 
constituted IRB/IEC prior to init iating the study and reapproval or review at least annually.  
Allergan is to be notified immediately if the re sponsible IRB/IEC has been  disqualified or if 
proceedings leading to disqualification have begun.  Copi[INVESTIGATOR_28078]/IEC correspondence 
with the investigator should be provided to Allergan. 
10.1.[ADDRESS_696491] ance with the applicable GCP regulations and 
guidelines. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 90 GDD-TA-T-004 v2013.9 
 10.1.4  Compliance With Electronic Reco rds; Electronic Signatures 
Regulations (US 21 CFR Part 11) 
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature. 
10.[ADDRESS_696492] not implement any devia tion from or changes of the protocol without 
approval by [CONTACT_535398]/favorable opi[INVESTIGATOR_120973]/IEC of a protocol amendment, except wher e necessary to eliminate immediate hazards 
to study patients, or when the changes involve on ly logistical or admini strative aspects of the 
study (eg, change in monitors, change of telephone numbers). 
10.3 Patient Confidentiality 
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study drug may ultimately be marketed, but the 
patient’s name [CONTACT_249626].  The patient's name [CONTACT_249627], Allerg an, or the governing hea lth authorities or the 
FDA if they inspect the study records.  Appr opriate precautions will be taken to maintain 
confidentiality of medical reco rds and personal information. 
10.3.1  Patient Privacy 
Written authorization (US sites only), data protection consent (European sites only), and other documentation in accordance with the rele vant country and local privacy requirements 
(where applicable) is to be obtained from each patient prior to enrollment into the study, and/or from the patient's legally authorized representative in accordan ce with the applicable 
privacy requirements (eg, the Health Insurance Port ability and Accountab ility Act Standards 
for Privacy of Individually Iden tifiable Health Information (“HIPAA”), European Union Data 
Protection Directive 95/46/ EC [“EU Directive”]). 
In accordance with HIPAA requirements, additional purposes of this study may include publishing of anonymous patient data from the study. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 91 GDD-TA-T-004 v2013.9 
 10.4 Documentation 
10.4.1  Source Documents 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 92 GDD-TA-T-004 v2013.9 
 10.4.2  Case Report Form Completion 
The investigator is responsible for ensuring that  data are properly recorded on each patient's 
case report forms and related documents.   
 
 
 
 
 
10.4.3  Study Summary 
An investigator's summary will be provided to Allergan within a short time after the 
completion of the study, or as designated by [CONTACT_287447].  A summary is also to be provided to 
the responsible IRB/IEC. 
10.4.4  Retention of Documentation 
All study related correspondence, patient r ecords, consent forms, patient privacy 
documentation, records of the distribution and us e of all investigational products, and copi[INVESTIGATOR_535353]. 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 93 GDD-TA-T-004 v2013.9 
 10.5 Labeling, Packaging, and Return or Disposal of Study 
Medications/Treatments 
10.5.1  Labeling/Packaging 
Packaged and labeled study medication will be supplied by [CONTACT_78562]. 
10.5.[ADDRESS_696493] supervis ion of an investigator. 
10.5.3  Return or Disposal of Study Medications/Treatments and/or 
Supplies 
All clinical study medications/treatments and/or  supplies will be returned to Allergan or 
Allergan designee for destruction.   
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696494] 
on-site visits to review, audit and copy study- related documents.  These representatives will 
meet with the investigator(s) and appropriate staff at mutua lly convenient times to discuss 
study-related data and questions. 
10.7 Handling of Biological Specimens  
Laboratory specimens for blood chemistry pa nel, hematology including complete blood 
count with differential, and urinalysis will be  sent to a centralized clinical laboratory 
(  
) with certification from a recognized ac creditation agency  
) to 
be assayed using validated methods.  
 
 
 
 
 
10.[ADDRESS_696495] joint cooperation betw een multiple investig ators and sites and 
Allergan personnel.  Authorship will be establis hed prior to the writing of the manuscript.  As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicen ter study except as agreed with Allergan. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 95 GDD-TA-T-004 v2013.9 
 10.9 Coordinating Investigator 
A signatory Coordinating Investigator [INVESTIGATOR_535354]. 
11. References 
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship 
between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 
2000;130:429-440. 
American Academy of Ophthalmology Glau coma Panel. Prefe rred Practice Pattern® 
Guidelines. Primary open-angle glaucoma. San Francisco, CA: American Academy of 
Ophthalmology; 2010a. 27 p. 
Budenz DL. A clinician's guide to the asse ssment and management of nonadherence in 
glaucoma. Ophthalmology. 2009;116:S43-S47. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year 
double-masked comparison of bimatoprost with timo lol in patients with glaucoma or ocular 
hypertension. Surv Ophthalmol. 2004;49 (Suppl 1):S45-S52. 
Cook C, Foster P. Epi[INVESTIGATOR_78532]:  What’s new?  Can J Ophthalmol. 
2012;47:223-226. 
Friedman DS. Introduction: new insights on e nhancing adherence to topi[INVESTIGATOR_78533]. Ophthalmology. 2009;116:S29. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 96 GDD-TA-T-004 v2013.9 
 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of 
intraocular pressure and glaucoma progression : results from the Early Manifest Glaucoma 
Trial. Arch Ophthalmol. 2002;120:1268-1279. 
Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, et al. 
One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular 
hypertension. Arch Ophthalmol. 2002;120:1286-1293. 
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Ke ltner JL, Miller JP, et al. The Ocular 
Hypertension Treatment Study: a randomized tria l determines that topi[INVESTIGATOR_78534]-angle glaucoma. Arch Ophthalmol. 
2002;120:701-713. Knight O’RJ, Lawrence SD. Sustained drug de livery in glaucoma. Current Opi[INVESTIGATOR_535355] 2014;25(2):112-117. Kozak KR, Crews BC, Morrow JD, Wang L-H, Ma  YH, Weinander R, et al. Metabolism of 
the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, 
thromboxane, and prostacyclin glycerol esters and ethanolam ides. J Biol Chem. 
2002;277:[ZIP_CODE]-[ZIP_CODE]. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and 
discussion of new evidence. Surv Ophthalmol. 2004;49(Suppl 1):S5-11. 
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical 
outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment 
randomized to medications or surg ery. Ophthalmology. 2001;108:1943-1953. 
LUMIGAN
® [Package Insert]. Irvine, CA: Allergan, Inc. 2012. 
Matias I, Chen J, De Petrocellis L, Bisogno T,  Ligresti A, Fezza F, et al. Prostaglandin 
ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther. 
2004;309:745-757. 
Mosaed S, Dustin L, Minckler DS. Comp arative outcomes between newer and older 
surgeries for glaucoma. Trans Am Ophthalmol Soc. 2009;107:127-33. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 
1996;80:389-393. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696496] e with glaucoma worldwide in 2010 and 2020. 
Br J Ophthalmol. 2006;90:262-267. Doi: 10.1136/bjo.2005.081224. Downloaded from 
bjo.bm.com, April 9, 2014. 
Stamper RL, Lieberman MF, Drake MV , eds. Introduction and Classification of the 
Glaucomas. In: Stamper RL, Lieberman MF, Drak e MV , editors. Becker-Shaffer's Diagnosis 
and Therapy of the Glaucomas, 8th ed. Amsterdam, Netherlands: Mosby [CONTACT_54469]; 2009;Chap 1:1-7. 
Tsai JC. A comprehensive perspective on patient adherence to topi[INVESTIGATOR_78535]. 
Ophthalmology. 2009;116:S30-S36. 
Varma R, Lee PP, Goldberg I, Kotak S. An asse ssment of the health and economic burdens of 
glaucoma. Am J Ophthalmol. 2011;152:515-522. Weber A, Ni J, Ling KH, Acheampong A, Ta ng-Liu DD, Burk R, et al. Formation of 
prostamides from anandamide in FAAH knockout mice analyzed by [CONTACT_535399]. J Lipid Res. 2004;45:757-763. 
Weinreb RN, Kaufman PL. The Glaucoma Research Community and FDA look to the future:  
a report from the NEI/FDA CDER Glauco ma Clinical Trial Design and Endpoints 
Symposium. Inv Ophthalomol & Vis Sci. 2009;50(4):1497-1505. 
Williams RD, Cohen JS, Gross RL, Liu CC, Sa fyan E, Batoosingh AL. Long-term efficacy 
and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular 
hypertension: year 4. Br J Ophthalmol. 2008;92:1387-1392. 
Woodward DF, Chan MF, Burke JA, Cheng-Bennett A, Chen G, Fairbairn CE, et al. Studies 
on the ocular hypotensive effects of prostagl andin F2 alpha ester prodrugs and receptor 
selective prostaglandin analogs. J Ocul Pharmacol. 1994;10:177-193. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM. The pharmacology of 
bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337-S345. 
Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J, et al. Bimatoprost: A novel 
antiglaucoma agent. Cardiovasc Drug Rev. 2004;22:103-120. 
Yu M, Ives D, Ramesha CS. Synthesis of pr ostaglandin E2 ethanolamide from anandamide 
by [CONTACT_78596]-2. J Biol Chem. 1997;272:[ZIP_CODE]-[ZIP_CODE].  
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696497] Characteristics will be supplied to 
investigators in countries where timolol (study-provided eye drops) is marketed. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 99 GDD-TA-T-004 v2013.9 
 12.2 Glossary of Abbreviations 
Term/Abbreviation Definition 
ABMD Anterior Basement Membrane Disease 
AC Anterior chamber 
ARMD Age-related Macular Degeneration 
ASC Ambulatory Surgical Center 
AS-OCT Anterior segment op tical coherence tomography 
BCV A Best-corrected visual acuity 
BID Twice daily 
BLQ Below the limit of quantitation 
CRF Case report form 
DMEK Descemet’s Membrane Endothelial Keratoplasty 
DSEK Descemet’s Strippi[INVESTIGATOR_535356]-to-treat 
IV/WRS Interactive voi ce/web response system 
MedDRA Medical Dictionary for Regulatory Activities 
MMRM Mixed-effects model repeated measures 
NI Noninferiority 
NSAID Non-steroidal anti-inflammatory drug 
OAG Open-angle glaucoma 
OCT Optical coherence tomography 
OHT Ocular hypertension 
OU Both eyes 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 100 GDD-TA-T-004 v2013.9 
 Term/Abbreviation Definition 
PAS Peripheral anterior synechiae 
PLA Polylactic acid 
PLGA Polylactic-co -glycolic acid 
POAG Primary open-angle glaucoma 
PP Per protocol 
RBC Red blood cell 
SC/T Patients with sickle cell disease or trait or other 
hemoglobinopathies 
SOC System Organ Class (MedDRA) 
SR Sustained release 
US [LOCATION_002] 
WBC White blood cell 
  
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 101 GDD-TA-T-004 v2013.9 
 12.3 Protocol Amendment Summary 
12.3.1 Amendment 1 
Title:  The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or 
Ocular Hypertension 
Protocol 192024-092 Amendment 1 
Date of Amendment:  August 2015 
Amendment Summary 
This summary includes changes made to Protocol 192024-092 (approved September 2014).  
This protocol was amended to clarify some s ections and to modify the inclusion/exclusion 
criteria. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these change s.  Minor editorial a nd document formatting 
revisions have not been summarized. 
 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 102 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
Title 
Page Updated Allergan Medical Safety Physician and Allergan Signatory information.  
Protocol Summary Updated and reordered the following key inclusion criteria as follows: 
• Diagnosis of either OAG (ie, primary OAG, 
pseudoexfoliation glaucoma, or pi[INVESTIGATOR_11232]) 
or OHT in each eye, and both eyes require 
IOP-lowering treatment (Note:  diagnosis does not have 
to be the same in both eyes) 
• In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated adequately with timolol topi[INVESTIGATOR_535339]-blocker (eg, timolol) eye drops as the sole therapy 
• In the opi[INVESTIGATOR_871]’s opi[INVESTIGATOR_1649], based on 
prior use or on IOP rebound (elevation) during the 
washout period, patient is a responder to IOP lowering 
by [CONTACT_12523][INVESTIGATOR_535326], prostaglandins, or 
prostaglandin analogs  either eye can be treated 
adequately with topi[INVESTIGATOR_358141], prostaglandin, or 
prostaglandin analog (eg, LUMIGAN, Xalatan, 
Travatan) eye drops as the sole therapy 
• The iridocorneal angle inferiorly in the study eye must 
be confirmed as being qualified by [CONTACT_535400]-OCT assessment 
• In both eyes, aAt the Baseline visit:  Hour 0 IOP in the 
study eye of ≥  22 mm Hg and ≤ 32 mm Hg, and in the 
fellow eye of  ≥ 17 mm Hg and ≤ 32 mm Hg, with 
difference between eyes of ≤ 5 mm Hg 
• In both eyes At Hour 2 at the Baseline visit:  Hour 2 
IOP in the study eye of ≥ 19 mm Hg and ≤ 32 mm Hg, 
and in the fellow eye of ≥ 14 mm Hg and ≤ 32 mm Hg  
Updated the following key exclusion criterion: 
• In the investigator’s opi[INVESTIGATOR_1649], patient is nonresponsive 
to topi[INVESTIGATOR_535325] -blockers and/or topi[INVESTIGATOR_535357], prostaglandins, or prostaglandin analogs 
(eg, LUMIGAN, Xalatan, Travatan) Revised key entry criteria based on 
the updated inclusion and exclusion criteria in the body of the protocol. 
 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 103 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
Section 
1.3.3 The objective of this stage of the study is to evaluate the 
safety and intraocular pressu re (IOP)-lowering efficacy of 
Bimatoprost SR in patients with OAG. 
As of March 2015April, 2014, a total of 87 109 patients had 
received a single administration;  and of those as of June 
2015, [ADDRESS_696498] 12 to 16 weeks after dosing.  Of the 67 
patients across all dose groups who had reached the Week 
16 visit, 62 (92.5%) had not required the use of additional 
intraocular pressure-lowering topi[INVESTIGATOR_535358].  A total of [ADDRESS_696499] SR (2 at 6 µg, 5 at 10 µg, and 
5 at 15 µg), providing up to [ADDRESS_696500] dose in 
the 6 µg group, 14 to 33 weeks (14, 16, 19, 24, and 33 
weeks) in the 10 µg group, and 17 to 37 weeks (17, 19, 19, 
26, and 37 weeks) in the [ADDRESS_696501] SR has shown 
an acceptable safety profile  with single and repeat Updated the summary of data from 
Study 192024-041D with more current results. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696502] 
frequently reported adverse events (> 10% of patients) for 
the study eye have been conjunctival hyperaemia, 
conjunctival haemorrhage, eye pain, foreign body sensation, 
and lacrimation increased.  Most of these adverse events 
were ocular, mild in severity, occurred within the first 
[ADDRESS_696503] been observed after the second treatment.  Please refer 
to the Investigator’s Brochure for details on reported safety 
findings. 
Sections 3 and 4.1 Updated the number of study sites from 170 to 180. Updated the number of study sites based on a revised estimate of 
global participating sites. 
Section 
4.3 Updated the following inclusion criteria: 
4.  Patient is willing to withhold his/her IOP-lowering 
treatments according to the study requirements, and in the 
opi[INVESTIGATOR_535359].   
 
 
 
 
7. 
 Diagnosis of either OAG (ie, primary pseudoexfoliation, 
or pi[INVESTIGATOR_535360] o
ma) or OHT  in each eye and both eyes 
require IOP-lowering treatment.  (Note:  diagnosis does not 
have to be the same in both eyes) 
8.  In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated adequately with topi[INVESTIGATOR_535361]-blocker (eg, 
timolol) eye drops as the sole therapy. Updated inclusion criteria 4, 7, and 8 for better clarity.   
 Added the following inclusion criterion: 
9.  In the investigator’s opi[INVESTIGATOR_1649], either eye can be treated 
adequately with topi[INVESTIGATOR_358141], prostaglandin, or 
prostaglandin analog (eg, LUMIGAN, Xalatan, Travatan) 
eye drops as the sole therapy.  
Removed the following original inclusion criterion:  
11.  In the opi[INVESTIGATOR_535362] (elevation) during the Washout period, 
patient is a responder to IOP lowering by [CONTACT_12523][INVESTIGATOR_535357], prostaglandins, or prostaglandin analogs (eg, 
LUMIGAN, Xalatan, Travatan)  
 Replaced original inclusion criterion 
[ADDRESS_696504] been re-
implanted based on the “investigator’s opi[INVESTIGATOR_1649]” for getting 
the injection. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 105 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
 Updated the following inclusion criteria: 
13.  At the Baseline visit: 
a. Hour 0 IOP in the study eye of ≥ 22 mm Hg 
and ≤ 32 mm Hg, and in the fellow eye 
of  ≥ 17 mm Hg and ≤ 32 mm Hg, with 
difference between eyes of ≤ 5 mm Hg 
b. Hour 2 IOP in the study eye of ≥ 19 mm Hg 
and ≤ 32 mm Hg, and in the fellow eye of 
≥ 14 mm Hg and ≤ 32 mm Hg 
14.  Central Corneal Endothelial Cell Density by [CONTACT_239795]:  Updated criteria 13 and 15 because 
the study d
esign is not paired eye 
comparison and to ease entry criteria related to nonstudy eye.  
Updated criterion 14 to make the 
automated specular microscopy count consistent with the Reading 
Center manual count. 
Section 
4.4 Updated the following exclusion criterion: 
3.  Known allergy or sensitivity to theany study medication 
or its components, any component of the delivery vehicle, 
procedure-related materials, or diagnostic agents used 
during the study (eg, topi[INVESTIGATOR_15413], dilating drops, fluorescein)  Revised exclusion criterion 3 for 
clarity.   
  
 Removed the following original exclusion criterion: 
6.  Patients who plan for an extended absence away from 
the area of the study center that would preclude them from 
returning for all protocol-specified study visits Exclusion criterion 6 was deleted to allow flexibility when possible. 
 Updated the following inclusion criteria: 
7.  Anticipated use of oral, intramuscular, or intravenous (IV) corticosteroids from [ADDRESS_696505] more than 1 year in advance.   
 11.  In the investigator’s opi[INVESTIGATOR_1649], patient is nonresponsive 
to topi[INVESTIGATOR_535325] -blockers and/or topi[INVESTIGATOR_535357], prostaglandins, or prostaglandin analogs (eg, 
LUMIGAN, Xalatan, Travatan) Revised exclusion criterion [ADDRESS_696506] and/or traumatic angle 
recession in either the study eye Revised exclusion criteria12,  
and 16 because this is not a paired 
eye comparison design; therefore, history only needs to be from the 
study eye.   

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 106 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 107 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
Section 
4.5.1 Revised the following:  Intermittent use of ocular decongestants or antihistamines is allowed if not taken within 2 weeksdays prior to a scheduled visit and/or ≤ 15 
minutes before or after topi [INVESTIGATOR_535341]. 
Added the following: Required surgical procedures may be 
performed in the fellow eye only after completion of Week 
52. 
Updated as follows: Note that in the event that the 
investigator performs an unan ticipated incisional surgical 
procedure on the study eye during which ocular fluid is to 
be removed, ocular fluid/implant samples may be collected for analysis (see Protocol Procedure Manual for further 
details).) at the investigator’s discretion. Decreased to [ADDRESS_696507] required surgery after the 
treatment period has been completed.   
 
Revised  the description of ocular 
fluid collection for clarity. 
Section 
4.5.2 Nonstudy IOP-lowering Medications 
Use of any topi[INVESTIGATOR_535363], other than use of study medication (timolol) in Control group or fellow eyes, is prohibited as 
concurrent therapy in either eye during the study through 
Week 52, unless necessary for the safety of the patient due 
to inadequate control of IOP as determined by [CONTACT_093].  NonstudyInadequate control of IOP should be 
confirmed at a subsequent visi t (scheduled or unscheduled 
visit).  Prior to Week [ADDRESS_696508] to the need for additional nonstudy IOP -lowering 
medication for safety reasons.  After the Week 52 visit, 
nonstudy topi[INVESTIGATOR_15434]-lowering medications will be 
permitted after the Week 52 visit, if in the investigator’s 
clinical judgment the IOP is not adequately controlled at 
two consecutive visits at least [ADDRESS_696509] SR (or Sham) administration in either eye is 
prohibited. 
Contact [CONTACT_535401]-provided eye drops and patients should wait at least 
[ADDRESS_696510] lenses.    

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 108 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
after instilling topi[INVESTIGATOR_15416]. 
Other Medications 
• Surgical procedures that are not related to Bimatoprost 
SR (or sham) administration procedures in either eye 
the study eye.  (Surgical pr ocedures are allowed in the 
fellow eye after Week 52 as described in Section 4.5.1) 
• Use of any nonstudy topi[INVESTIGATOR_20718] 
(except as described above and in Section 4.5.1) in either eye 
• Use of soft contact [CONTACT_72061] [ADDRESS_696511] SR (or Sham) administration in either eye  
Section 
4.5.3 For women of childbearing potential who may participate in the study, the following methods of contraception, if 
properly used, are generally considered reliable:  hormonal 
contraceptives (ie, oral, patch, injection, implant), male condom with intravaginal spermicide, diaphragm or 
cervical cap with spermicide, vaginal contraceptive ring, 
intrauterine device, surgical sterilization (bilateral tubal 
ligation, bilateral salpi[INVESTIGATOR_1656]), vasectomized partner, or 
true sexual abstinence, when this is in line with the 
preferred and usual lifestyle of the subject. 
 Upda
ted text for clarity. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696512] received nons tudy topi[INVESTIGATOR_148511] P- lowering 
medication (prohibited before Week 52 unless required for 
safety reasons due to inadequate IOP control and attested to 
by [CONTACT_093]) in a Bimatoprost SR study eye will 
receive Sham administration in that eye on the Bimatoprost 
SR repeat administration day(s). 
 
Patients who use nonstudy IOP-lowering medication 
(prohibited before Week 52 unless required for safety 
reasons due to inadequate IOP control and attested to by [CONTACT_1275]) in only one eye will be followed for the 
duration of the study. 
 Updated text for clarity.   
 
  
 
  
 
  
 
  
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 110 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
Section 
6.2 Biomicroscopic Examination:  Biomicroscopic 
examinations will be performed using a slit lamp.  The examinations will include evaluation of the condition of the 
eyelids, conjunctiva, cornea,  AC, iris/pupil, and lens 
(through a dilated pupil). 
Lens Assessment (Phakic Eyes Only):   Biomicroscopic 
findings will be evaluated for the presence and severity of 
nuclear, cortical, and posterior subcapsular lens opacities.  
See the Protocol Procedure Manual for further details. 
Specular Microscopy:   Endothelial cell density will be 
assessed using specular microscopy performed on the 
central cornea at all sites.  Th e final qualification of central 
endothelial cell density for study entry will be determined by [CONTACT_535402]..  Qualification will remain valid for 
1 year after Screening in patie nts who are not enrolled at the 
time of Screening, if in the investigator’s opi[INVESTIGATOR_535364] 
(eg, ocular surgery) during that time.  All additional 
specular microscopy images taken during the study will be assessed by [CONTACT_66322].  See the Protocol 
Procedure Manual for further details.  The same instrument 
should be used throughout the study for a given patient. 
Anterior Segment Optical Coherence Tomography 
(AS-OCT):   AS-OCT measurements will be performed at 
all sites as a criterion for in clusion and a Reading Center 
will be used to confirm patient iridocorneal angle size and 
determine eligibility.  Each patient’s iridocorneal angle eligibility is valid for the duration of the study; however, if 
in the investigator’s opi[INVESTIGATOR_535365]’s angle size may 
have changed, an unscheduled AS-OCT may be performed prior to retreatment.  Qualification will remain valid for 
1 year after Screening in patie nts who are not enrolled at the Updated text for clarity.  Defined a time frame and requirements for the 
validity of the qualifications 
provided by [CONTACT_66322]. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 111 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
time of Screening, if in the investigator’s opi[INVESTIGATOR_535366]).  
See the OCT Image Acquisition manuals from the Reading 
Center for further details on the use of OCT.  In the event that the AS-OCT type as specified in the manuals is not 
available, a suitable altern ative may be approved by 
[CONTACT_535403].  The 
same instrument should be used throughout the study for a 
given patient. 
Section 
8.[ADDRESS_696513]-
dilation activities should be maintained.  Intraocular 
pressure should be measured at approximately the same 
time of day at each visit.  Hour  0 (H0) is 8 AM ± 1 hour and 
Hour 2 (H2) is 2 hours after Hour  0  (± 30  minutes).  
Study-provided eye drop medications should be 
administered immediately afte r performing the Hour [ADDRESS_696514] be completed prior to performing any examination 
procedures that require pupil dilation. Updated text for clarity. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696515] SR or Sham 
administration. at which time they should complete the 
Month 20/Exit visit procedures. Updated text for clarity. 
Section 8.[ADDRESS_696516] administration (or Sham), failure to undergo 
an Administration visit does not indicate total withdrawal 
from the study.  Patients who have received nonstudy 
IOP-lowering medication in only one eye will be followed 
for the duration of the study.  Patients who have received 
nonstudy IOP-lowering medication in both eyes, or patients 
who do not undergo Cycle 2 or 3 (or both) administrations 
(or Sham administrations), will still be followed for [ADDRESS_696517] SR or Sham 
administration for safety reasons.  These patients are 
eligible for Early Discontinuation (Early Exit) as described 
in Section 8.8, above. 
•Patient develops (or has an exacerbation of) a medical condition that, in the opi[INVESTIGATOR_871], would 
putcompromises the patient at an unacceptable medical risk 
by [CONTACT_535404]’s ability to participate in the study 
participation 
If a patient develops (or has an exacerbation of) a medical 
condition that, in the opi[INVESTIGATOR_871], would put 
the patient at an unacceptable  medical risk by [CONTACT_535405], the patient will be withdrawn from the 
study. Updated text for clarity, as in this study design, patients are followed 
for [ADDRESS_696518] 
injection (or Sham) for safety purposes, and cessation of injection 
does not constitute study 
withdrawal. 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 113 GDD-TA-T-004 v2013.9 
 12.3.2 Amendment 2 
Title: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or 
Ocular Hypertension 
Protocol 192024-092 Amendment 2 
Date of Amendment: March 2017 
Amendment Summary 
This summary includes changes made to Protocol 192024-092 Amendment 1 (approved 
August 2015). This protocol was amended to ch ange the screening re quirement for angle 
eligibility confirmation in the study eye, modify/clarify the inclusion/exclusion criteria, clarify the statistical analyses, and change addi tional procedures for patients with sickle cell 
disease from required to optional. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these cha nges. Minor editorial and document formatting 
revisions have not been summarized. 
Section Revision Rationale 
Protocol 
Summary Removed text from the visit schedule section referring to reading center confirmation of iridocorneal angle: 
• Screening (up to 28 days); Washout period of up to 42 days for both eyes (which may begin once 
screening procedures have be en completed and the site 
has obtained confirmation of anterior segment optical 
coherence tomography [AS-OCT] iridocorneal angle 
qualification from the Reading Center); Baseline 
(Days -3 to -1 up to 3 days) 
Updated the following key inclusion criteria: 
• The iridocorneal angle in the study eye must be 
independently confirmed as being qualified by 
[CONTACT_535406]-OCT assessment 
2 ophthalmologists using the following criteria: 
a. Shaffer Grade ≥ 3 on clinical gonioscopy of 
the inferior angle 
b. Peripheral anterior chamber depth by [CONTACT_535407] ≥ 1/2 corneal thickness 
Note: The independent eligibility assessments must 
both agree that the Shaffer grade is ≥ 3 and the Van 
Herick grade is ≥ 1/2 corneal thickness. 
• At the Baseline visit: Hour 0 IOP in the study eye of ≥ 22 mm Hg and ≤ [ADDRESS_696519] changes in the body of the protocol. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 114 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
≥ 17 mm Hg and ≤ 32 mm Hg, with difference 
between eyes of ≤ 5 mm Hg 
• At the Baseline visit: Hour 2 IOP in the study eye of 
≥ 19 mm Hg and ≤ 32 mm Hg, and in the fellow eye of 
≥ 14 mm Hg and ≤ 32 mm Hg 
• By [CONTACT_535372], the final central endothelial cell density in both eyes must be confirmed as being qualified by [CONTACT_535373], with at least 
one eye qualified for inclusion as the study eye 
Updated the following key exclusion criterion: 
• The following surg ical history: 
a. History or evidence of complicated cataract 
surgery in the study eye:  eg, surgery resulting in 
complicated lens placement (such as anterior 
chamber intraocular lens implant (IOL); phakic 
IOL; sulcus IOL; aphakia, etc) or intraoperative 
complications (eg such as a posterior capsular tear 
[with or without vitreous loss], substantial iris 
trauma, etc) 
Note: history of uncomplicated cataract surgery is 
not an exclusion. 
b. History of phakic IOL insertion for refractive 
error correction in the study eye 
Updated the statistical analyses as follows: 
• Intraocular pressure change from baseline will be 
analyzed using a mixed-effects model repeated measures (MMRM) approach. The model will include the fixed effects of tr eatment; IOP time-matched 
change from baseline IOP stratification; visit ( as the 
response variable and treatment, timepoint (Hours 0 
and 2 at each visit of Weeks 2, 6, and 12), hour; the 
two-way interaction between treatment and each of 
hour and visit; and the three-way treatment-by-
timepoint interaction between treatment, hour, and 
visit and baseline IOP stratif ication as fixed effects. 
Unstructured covariance matrix will be used for 
repeated measures on the same patient; if the model 
with unstructured covariance matrix fails to converge, 
multiple imputation (MI) will be implemented before 
MMRM. 
• For the [LOCATION_002] Food and Drug Administration 
(US FDA), the primary efficacy variable will be the 
study eye time-matched IOP.  The primary analysis 
will be based on Weeks 2, 6, and 12 using the ITT population.  Specifically, the following analysis will be 
performed:  time-matched IOP will be analyzed using 
an MMRM approach based on the same model as 
described for the primary efficacy analysis of time-
matched IOP change from baseline.   
• Sample Size Calculation:  The sample size calculation is based on the primary efficacy analysis of the 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 115 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
time-matched IOP for US FDA review because the 
sample size based on the primary efficacy analysis for 
other regions is expected to be smaller. 
Section 
1.3.1 Nonclinical studies with pharmacology endpoints (Reports BIO-09-803, BIO-11-920, PK09109-PK, BIO-09-785) 
showed dose-related reductions in IOP in normotensive 
Cynomolgus monkeys and Beagle dogs, as well as in laser-induced ocular hypertensive Cynomolgus monkeys 
following single doses.  Toxicolo gy studies, of at least [ADDRESS_696520] SR administration, were conducted in 
Cynomolgus monkeys and Beagle dogs (TX09051-TX, TX09066-TX, TX10016-TX, TX11076-TX, TX12012-TX, 
TX12018-TX, and TX12102-TX-I1 [ongoing]).  Monkeys, 
which have a characteristically small anterior chamber 
angle compared to both dogs and humans, did not tolerate 
Bimatoprost SR dose strengths tested ( ≥ [ADDRESS_696521] 
SR) due to chronic contact [CONTACT_535408].  Single and repeat ocular toxicity studies with Generation [ADDRESS_696522] SR in dogs with varying AC 
angle sizes demonstrated acc eptable safety and ocular Updated information from completed studies 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 116 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
tolerability with single doses ≤ 20 µg (TX11076 TX, 
TX12012-TX, TX12018-TX) and with repeat doses of 
≤ 15 µg (TX12012 TX, TX12018-TX).  Furthermore, no 
adverse drug- or implant-related ocular findings have been 
seen following three in tracameral injections of up to 20 µg 
(two 10 µg implants) Bimatoprost SR (9 month timepoint 
including histopathology) in the ongoing 18-month repeat 
dose Good Laboratory Prac tice (GLP) study in dogs 
(Report TX12102 TX). 
Pharmacokinetic studies (PK09109 PK, PK11086-PK) in Beagle dogs demonstrated th at systemic exposure of 
bimatoprost and bimatoprost acid was below the limit of 
quantitation (BLQ) with doses ≤ 60 µg.  Aqueous humor 
concentrations generally peaked by 10 weeks postdose for 
doses ≤ 30 µg (Generation 1 and Generation 2), then 
declined to low levels suggestive of near-complete drug release from the device at 3 months for doses ≤ 20 µg.  By 
14 weeks following a 20 µg (Generation 2) dose, ocular 
tissues samples were collected for analysis, which demonstrated that drug and metabolite concentrations were BLQ in aqueous humor, vitreous humor, retina, and the 
remnant implants, but detected in cornea, choroid, and iris-
ciliary body. A pharmacokinetic study (PK14025-PK) was 
conducted in Beagle dogs comp aring the ocular distribution 
of topi[INVESTIGATOR_358149] 0.03% solution or a single 
Generation [ADDRESS_696523] SR implant (15 µg).  Following 
topi[INVESTIGATOR_78086], bimatoprost and bimatoprost acid 
distributed into the iris-ciliary  body as well as other (off 
target) tissues with concentrations in the bulbar 
conjunctiva, eyelid margin, and periorbital fat significantly 
higher than those observed in the iris-ciliary body. In 
contrast, following administration of a single Generation [ADDRESS_696524] acid concentrations were either below the limit 
of quantitation (BLQ) or near the detection limit in bulbar 
conjunctiva, eyelid margin, and periorbital fat while the 
highest bimatoprost and bimatoprost acid concentrations 
were observed in the target tissue, the iris ciliary body. 
Retinal concentrations were BLQ following both topi[INVESTIGATOR_535367]. 
Section 1.3.3 Study 192024-041D is an ongoing was a Phase 1/2, paired-
eye comparison evaluating the safety and efficacy of [ADDRESS_696525] SR (6  µg, 10 µg, 15 µg, or 20 µg 
[2 × 10 µg implants]), as single or repeat administration in 
one eye (study eye), versus the use of topi[INVESTIGATOR_78499]
® 
0.03% in the fellow eye (nonst udy eye).  The objective of 
this study is was to evaluate the safety and IOP-lowering 
efficacy of Bimatoprost SR  in patients with OAG. 
As of March 2015, a total of 109 patients had received a 
single administration; and as of June 2015, [ADDRESS_696526] SR.  Based 
on a review of the efficacy data as of March 2015, a A 
trend in dose response has been  was observed across the 4 Updated information from recently 
completed study 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696527] been were observed after the 
second treatment.  Please re fer to the Investigator’s 
Brochure for details on reported safety findings. 
Section 
4.2 The study population consists of patients with OAG or OHT and an open iridocorneal angle inferiorly by [CONTACT_535409] e, and OAG or OHT in the 
fellow eye, where both eyes require IOP-lowering medication.  The eye that meets the entry criteria (Sections 4.3 and 4.4) will be selected as the study eye.  If 
both eyes meet the entry crite ria (including iridocorneal 
angles that have been confirmed as qualified by [CONTACT_535410] [AS-OCT assess ment]), the eye with the 
higher IOP at Baseline Hour [ADDRESS_696528] and specular 
microscopy assessment respectively (see Protocol 
Procedure Manual for details). Revised for consistency with 
updated inclusion criteria 
Section 4.2.1 4.2.1 Patients With Sickle Cell Trait or Disease 
At screening all patients will be tested for sickle cell trait or 
disease.  Patients with sickle cell trait or disease (or other 
hemoglobinopathies) may be enrolled at the discretion of 
the investigator based on an individual risk-benefit 
assessment.  Because of a slightly higher risk of IOP 
elevation and intraocular complications in the setting of a microhyphema, patients with these disorders must may 
undergo optional additional safety monitoring 
(biomicroscopy and IOP measurements) after 
injection/Sham injection at the investigator’s discretion (as 
outlined in see Section 8.4).  Additional information about 
the Bimatoprost SR experience in patients with sickle trait is provided in the Investigator’s Brochure. Based on the ongoing safety monitoring of the 192024-091 and 192024-092 studies, no increased 
risk of hyphema or microhyphema 
with sickle cell traits or sickle cell disease is confirmed. There are 
400+ patients had at least one 
Bimatoprost SR injection in the 2 studies (estimated based on 1:1:1 
ratio), there is only one report of 
microhyphema in a NON-sickle cell 
patient. No anterior chamber safety 
concerns reported in the 14 sickle 
cell or traits patients. 
Section 10. The iridocorneal angle in the study eye inferiorly in Inclusion criterion for angle 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696529] be open based on clinical gonioscopic 
examination independently confirmed as being qualified by 
2 ophthalmologists using the following criteria: 
a. Shaffer Grade ≥ 3 on clinical gonioscopy of the inferior 
angle 
b. Peripheral anterior chamber depth by [CONTACT_535411] ≥ 1/2 corneal thickness 
Note: The independent eligibility assessments must both 
agree that the Shaffer grade is ≥ 3 and the Van Herick 
grade is ≥ 1/[ADDRESS_696530] assessment 
13 12a. Hour 0 IOP in the study eye of ≥ 22 mm Hg and 
≤ 32 mm Hg, and in the fellow eye of ≥ 17 mm Hg and 
≤ 32 mm Hg, with difference between eyes of ≤ 5 mm Hg 
13 12b. Hour 2 IOP in the study eye of ≥ 19 mm Hg and 
≤ 32 mm Hg, and in the fellow eye of ≥ 14 mm Hg and 
≤ 32 mm Hg 
14 13b. By [INVESTIGATOR_31975]:  final central endothelial cell density 
in both eyes must be confirmed as being qualified by 
[CONTACT_535373], with  at least one eye qualified 
for inclusion as the study eye assessment revised to use clinical measures in order to develop a 
more “real-life” measure of angle 
openness.  
 
 
 
  
 
 
Lower limit of IOP in fellow eye 
removed to allow for flexibility in 
enrollment. Fellow eye IOP upper 
limit is required for safety purposes, but lower limit is not included in 
analysis. 
 
Revised for clarity; at least one eye 
needs to be qualified as study eye 
for patient to be included in the 
study. 
Section 4.[ADDRESS_696531] SR 
Study 192024-041D 
12. History or evidence of a clinically relevant, substantial 
ocular trauma (eg, a traumatic cataract, and/or traumatic 
angle recession, etc) in the study eye 
13. The following surgical history: 
a. History or evidence of co mplicated cataract surgery in 
the study eye: eg, surgery resulting in complicated lens 
placement (such as anterior chamber intraocular lens 
implant ([IOL]);, phakic IOL;, sulcus IOL;, aphakia;, etc) 
or intraoperative complications (eg, such as a posterior 
capsular tear [with or without vitreous loss], iris trauma, 
etc). Note: history of uncomplicated cataract surgery is not 
an exclusion. 
b. History of phakic IOL insertion for refractive error 
correction in the study eye Revised  
because multiple studies 
are ongoing. 
Revised for clarity.  
 Revised for clarity 
 
   
 
  

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696532] SR or the Sham administration procedure, but will be masked to the specific implant dose 
strength.  The patient and the remaining staff will be 
masked to the patient’s treat ment assignment.  Efficacy 
IOP measurements will be masked by [CONTACT_2329] a 2-person 
reading method as described in Section 6.1.1 (for optional 
postoperative IOP measurements for patients with sickle cell disease or trait [or other hemoglobinopathies], see 
Section 8.4). Based on the ongoing safety monitoring of the 192024-091 and 192024-092 studies, no increased risk of hyphema or microhyphema 
with sickle cell traits or sickle cell 
disease is confirmed. There are 400+ patients had at least one 
Bimatoprost SR injection in the 
2 studies (estimated based on 1:1:1 
ratio), there is only one report of 
microhyphema in a NON-sickle cell 
patient. No anterior chamber safety 
concerns reported in the 14 sickle 
cell or traits patients. 
Section 5.9.4 Note:  Patients with sickle cell disease or trait (or other hemoglobinopathies) will be expected to may undergo 
optional biomicroscopy and IOP examination in both eyes 
[ADDRESS_696533] SR administration (or Sham administration).  This optional IOP examination is for 
postoperative purposes only, and as such does not require a masked, 2-person reading method.  The IOP should be taken only once to avoid excessive postadministration (or 
Sham administration) manipula tion of the eye, and should 
be taken by [CONTACT_093] (or other unmasked, qualified personnel).  This postadministration (or Sham 
administration) examination may be performed using a Goldmann applanation tonometer or a hand-held 
tonometer.  (See the Study Procedure Manual for details.) Based on the ongoing safety 
monitoring of the 192024-091 and 
192024-092 studies, no increased 
risk of hyphema or microhyphema with sickle cell traits or sickle cell 
disease is confirmed. There are 
400+ patients had at least one Bimatoprost SR injection in the 
2 studies (estimated based on 1:1:1 
ratio), there is only one report of 
microhyphema in a NON-sickle cell 
patient. No anterior chamber safety 
concerns reported in the 14 sickle 
cell or traits patients. 
Section 
6.2 Hematology, blood chemistry, and urinalysis:  Blood and urine samples will be collected for blood chemistry and 
hematology panels (including sickle cell testing by [CONTACT_102127]) and urinalysis. Based on the ongoing safety 
monitoring of the 192024-091 and 
192024-092 studies, no increased 
risk of hyphema or microhyphema with sickle cell traits or sickle cell 
disease is confirmed. There are 
400+ patients had at least one Bimatoprost SR injection in the 
2 studies (estimated based on 1:1:1 
ratio), there is only one report of microhyphema in a NON-sickle cell 
patient. No anterior chamber safety concerns reported in the 14 sickle cell or traits patients. 
 Visual Acuity:  Visual acuity tests will be performed at all scheduled visits except on any of the [ADDRESS_696534] refraction using Snellen equivalent with a logMar Revised for consistency with 
updated visit schedule 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 120 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 
chart (see Protocol Procedure Manual) will be performed at 
Screening;, Baseline;, Weeks 12, 28, 44, and 52;, and 
Month 20/Exit. 
Gonioscopy: Gonioscopic examination for eligibility at 
Screening (only) will be independently performed by 
2 ophthalmologists as described in the Protocol Procedure 
Manual. The independent eligibility assessors should not 
share their assessments with each other until the assessment 
is recorded. The 2 ophthalmologists’ independent 
eligibility assessments must confirm patient eligibility for 
participation in the study. Subsequent gonioscopic 
examinations will be performed by [CONTACT_1704]. 
Pachymetry:  Corneal thickne ss using ultrasound (contact) 
pachymetry will be performed on the central cornea at all 
sites..  The same instrument should be used throughout the 
study for a given patient.  Contact [CONTACT_535412] 2 IOP Measurement and 
before gonioscopymeasurement.  See the Protocol 
Procedure Manual for further details. Anterior Segment Optical Coherence Tomography 
(AS-OCT):  AS-OCT measurements will be performed at all sites as a criterion for in clusion and a Reading Center 
will be used to confirm patient iridocorneal angle size and 
determine eligibility.  Each patient’s iridocorneal angle 
eligibility is valid for the duration of the study; however, if 
in the investigator’s opi[INVESTIGATOR_535365]’s angle size may 
have changed, an unscheduled AS-OCT may be performed 
prior to retreatment.  Qualification will remain valid for 1 
year after Screening in patient s who are not enrolled at the 
time of Screening, if in the investigator’s opi[INVESTIGATOR_535368]) and a Reading Center will be used to examine angle 
size for investigational purposes.  See the OCT Image 
Acquisition manuals from the Reading Center for further details on the use of OCT.  In the event that the AS-OCT type as specified in the manual s is not available, a suitable 
alternative may be approved by [CONTACT_535403].  The same instrument should be used throughout the study for a given patient.  
 Revised for consistency with 
revised eligibility criteria 
 
  
 
 
Revised for consistency with visit 
schedule 
 
 
 
 
Revised for consistency with 
updated eligibility criteria 
Section [IP_ADDRESS] The blood tests performed at the screening visit will 
include testing for sickle cell disease or trait by a site-
selected and qualified local laboratory, as outlined in the 
Protocol Procedure Manual. Based on the ongoing safety monitoring of the 192024-091 and 192024-092 studies, no increased 
risk of hyphema or microhyphema 
with sickle cell traits or sickle cell disease is confirmed. There are 
400+ patients had at least one 
Bimatoprost SR injection in the 2 studies (estimated based on 1:1:1 
ratio), there is only one report of 
microhyphema in a NON-sickle cell 
patient. No anterior chamber safety 
concerns reported in the 14 sickle 
cell or traits patients. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696535] 
completed or prematurely discontinued before Week 52 and Month 20/Exit.  Analyses  will be performed after each 
lock.  Prior to the first database lock a detailed analysis plan will be finalized.  To maintain the integrity of the ongoing study, Allergan study personnel who are directly 
involved in data handling and supporting the trial (such as the clinical study team) will remain masked to treatment 
assignment of individual patients until during the study 
completion. To avoid potential data unmasking between 
locks and to protect trial integrity, study statistical 
personnel who have been unmasked after each lock will no 
longer be involved directly in any ongoing masked study 
conduct. Another statistician, who is still masked to study 
treatment, will assume these responsibilities until the next 
lock. Unmasked data handling and appropriate data and 
results access will be specifi ed prior to each lock. Updated text for clarity. 
Section 
7.2 To avoid confounding of efficacy data, IOP measurements obtained after initiating the use of nonstudy IOP-lowering medication in an eye will be treated as missing for that eye 
excluded from the calculation of the summary statistics and 
the statistical analyses for that eye but raw values will be 
presented in the listings. Updated text for clarity. 
Section 7.3.1 Intraocular pressure change from baseline will be analyzed using a mixed-effects model repeated measures (MMRM) approach.  The model will include the fixed effects of 
treatment; IOP time -matched change from baseline IOP 
stratification; visit (as the response variable and treatment, 
timepoint (Hours 0 and 2 at each visit of Weeks 2, 6, and 
12); hour; the two-way, treatment-by-timepoint interaction, 
between treatment and each of  hour and visit; and the 
three-way interaction between treatment, hour, and visit 
baseline IOP stratification as fixed effects. Unstructured 
covariance matrix will be used for repeated measures on 
the same patient; if the model with unstructured covariance 
matrix fails to converge, multiple imputation (MI) will be 
implemented before MMRM.  The details of the model 
specifications will be provided in the analysis plan. Updated text for clarity. 
Section 7.3.[ADDRESS_696536] the no-difference null 
hypothesis will be performed at scheduled visits (Weeks 2, 
6, and 12) and hours for (1) time-matched IOP and (2) 
time-matched IOP change from baseline. 
The analysis of time-matched IOP will be similarly 
performed as described above with time matched IOP 
replacing time-matched IOP change from baseline in the 
analysis model. Updated text for clarity. 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696537] SR dose strength which demonstrates efficacy (clinical noninferiority) as described in the primary efficacy analyses, se condary efficacy analyses 
comparing the Bimatoprost SR dose strength and timolol to test the no-difference null hypothesis will be performed at scheduled visits (Weeks 2, 6, and 12) and hours for time-
matched IOP. Updated text for clarity. 
Section 
7.7 The sample size calculation is based on the primary efficacy analysis of the tim e-matched IOP for US FDA 
review since the sample size based on the primary efficacy 
analysis for other regions is expected to be smaller. Updated text for clarity. 
Section 8.2 Patients currently being treated with IOP-lowering medication(s) in either eye will begin washout of these medication(s) following completion of the screening 
procedures and Reading Center confirmation of AS-OCT 
iridocorneal angle qualification. Revised for consistency with 
revised inclusion criterion 
 
 
Section 
8.[ADDRESS_696538] be confirmed by [CONTACT_535372]. Revised for consistency with revised inclusion criterion 
 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 123 GDD-TA-T-004 v2013.9 
 Section Revision Rationale 

 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-092 Amendment 3 
 
 124 GDD-TA-T-004 v2013.9 
 12.3.3 Amendment 3 
Title: The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or 
Ocular Hypertension 
Protocol 192024-092 Amendment 3 
Date of Amendment: June 2018 
Amendment Summary 
This summary includes changes made to Protocol 192024-092 Amendment 2 (approved 
March 2017). This protocol was amended to reduce the sample size. 
Following is a summary of content-oriented changes that were made to each section of the 
protocol, and a brief rationale for these cha nges. Minor editorial and document formatting 
revisions have not been summarized. 
Section Revision Rationale 
Title Page Change in Allergan signatory Personnel change 
Protocol 
Summary Number of Patients: Approximately 600 510 patients 
will be enrolled in the study. 
Sample Size Calculation: The sample size calculation 
is based on the primary effi cacy analysis of the IOP for 
US FDA review because the sample size based on the primary efficacy analysis for other regions is expected to be smaller. Based on simulations, a sample size of 
540 486 patients (180 162 per group) will provide 
approximately 95 95.1% and 81 83.5% power to show 
noninferiority (NI) of Bimatoprost SR [ADDRESS_696539] SR 10 µg, respectively, to timolol at all 6 
scheduled timepoints based on an NI margin of 1.5 mm Hg and at 3 or more timepoints based on an NI 
margin of 1.0 mm Hg. Assuming a premature 
discontinuation rate of 10 5% within 12 weeks (before 
the primary database lock), approximately 600 510 
patients (200 170 per group) are to be enrolled into this 
study. Updated to reflect changes in the body of the protocol. 
Section 4.1 Enrollment of approximately 600 510 patients in total 
at approximately 180 sites, with approximately 200 
170 patients per group, is planned to ensure 180 
162 completed patients per group, assuming a 
premature discontinuation rate of 10 5%. Revised based on new sample size calculation 
 
 
Approval Date :  
 05-Jun-2018Allergan Confidential  Protocol 192024-[ADDRESS_696540] with α = 0.[ADDRESS_696541] SR 10 µg and timolol is -0.25 mm Hg (ie, Bimatoprost SR 10 µg is 0.25 mm Hg better in IOP-lowering than timolol) at Weeks [ADDRESS_696542] correlation of 0.6.  It is was also assumed that the efficacy 
(IOP-lowering effect) of Bimatoprost SR [ADDRESS_696543] SR 10 µg by 0.25 mm 
Hg at each timepoint (Hours 0 and 2).  These 
assumptions are were made at the study design phase 
based on the data obtained from the ongoing clinical 
study 192024-041D. Based on simulations, a sample 
size of 540 patients (180 per group) will would provide 
approximately 95% and 81% power to show 
noninferiority (NI) of Bimatoprost SR [ADDRESS_696544] SR 10 µg, respectively, to timolol at all 6 scheduled timepoints based on an NI margin of 1.5 
mm Hg and at 3 or more timepoints based on an NI 
margin of 1.0 mm Hg.  Assuming a premature discontinuation rate of 10% within 12 weeks (before 
primary database lock), approximately 600 patients 
(200 per group) are were to be enrolled into this study. 
As part of ongoing centralized data monitoring of 
masked study data, some of the initial assumptions 
used for sample size calculation have been revisited. 
The rate of discontinued or rescued patients in the first 
12 weeks is approximately 5%, which was less than 
the rate of 10% assumed at  the study design phase. 
Furthermore, the masked common IOP variability 
(pooled standard deviation across treatments and 
timepoints) is approximately 3.[ADDRESS_696545] deviation of 3.8 mm Hg, a 
sample size of 486 patients (162 per group) would 
provide approximately 95.1% and 83.5% power to 
show NI of Bimatoprost SR [ADDRESS_696546] SR 
10 µg, respectively, to timolol at all 6 scheduled 
timepoints based on an NI margin of 1.5 mm Hg; and 
at 3 or more timepoints based on an NI margin of 1.0 
mm Hg. With the updated premature discontinuation 
or rescue rate of 5% within 12 weeks, approximately 
510 patients (170 per group) are to be enrolled into this 
study. Revised because the observed discontinuation rate and IOP variability are lower than initially 
assumed 
 
 
 
Approval Date :  
 05-Jun-2018ALLERGAN  
 
 
 
 
    
 
Date (DD/MMM/YYYY)/Time (PT)  Signed by:  [CONTACT_535413] 192024-092 Amd 3
05-Jun-2018 11:22 GMT-070 Clinical Development Approval
